Podcasts about omix

Sonntags um 10 wird zum Hochamt geläutet. Papst Alex und Kardinal Christoph rufen zum Gottesdienst und richten ihr Wort an die Gläubigen. Sie lesen die Kapitel 3260 bis 3264 aus der Heiligen Schrift der Perry Rhodan Hauptserie und stellen dabei fest, das Omix-7 nicht gleich Omega-7 ist. Ersteres ist der Titel eines Romans, letzteres ist eine ungesättigte Fettsäure, könnte aber auch ein SciFi-Film aus den 50ern sein.

Hosted on Acast. See acast.com/privacy for more information.

Cuma Raporu #213 podcastimizde, geçtiğimiz haftanın öne çıkan haberlerini derledik. Bakalım bu hafta neler olmuş? Konu başlıkları; 00:00 Giriş 03:12 OMIX Lansmanı 19:44 Nothing Phone (1) geliyor! 26:40 TCL 30 ve TCL 30+ Türkiye'de 28:35 Leica x Xiaomi: Xiaomi 12S detayları 38:04 TOGG için elektrikli araçlara ÖTV düzenlemesi geliyor 50:11 Huawei Mate XS 2 fiyatı açıklandı 53:12 Türkiye'de ilk maymun çiçeği vakası! 57:54 Red Bull'dan hiper otomobil: RB17 59:49 HBO Max Türkiye hazırlığını askıya aldı

Hoe verander je je businessmodel als je oude businessmodel niet meer werkt?Maurits Ouweneel is getrouwd met Marije en vader van twee kinderen. Na een studie Journalistiek werkte hij in de financiële dienstverlening, media en een aantal internetbedrijven. Vanaf 2005 begonnen zijn avonturen als ondernemer. En daar gaan we over in gesprek vandaag. Hoe hij tijdens de crisisperiode zijn businessmodel heeft om moeten gooien van een evenementenburo naar een  toonaangevende producent van zakelijke TV-, videocontent (talkshows & documentaires) en event producties (congressen & seminars).Zij bedenken en produceren wij spraakmakende en hoogwaardige producties voor opdrachtgevers én eigen formats. Buro van Oranje is onafhankelijk en heeft ervaring met zeer uiteenlopende opdrachtgevers: van multinationals, MKB, overheidsinstellingen, (commerciële) omroepen, uitgevers, brancheverenigingen tot professionele sprekers en bekende persoonlijkheden. Wij werken voor: RTL Nederland, Accenture, Funda, Sociale Verzekeringsbank, Essilor, Picnic, Jura Nederland, Omix, Vakmedianet, Distrifood, AFAS, Denkproducties e.v.a.In gesprek over de  volgende onderwerpen:De storm die coronacrisis heet, die roet in het eten gooit voor de evenementenbranche en de gevolgen daarvan.Kijken naar de mogelijkheden en ruimte in je hoofd makenHet ontstaan van Humberto Onderneemt met highlights als Pieter Zwart (Coolblue), de Oesterkwekerij in Yerseke en La Trappe BierOndernemerslessen die Maurits heeft geleerdVisie op het businessmodel en tarievenVisie op de evenementenbrancheLaat je inspireren door de boekentips van MauritsBiografie oprichter Nike, ShoedogBiografie Joop van den EndeGeef nooit korting - Jos BurgersDe scheidsrechter, Bjorn KuipersNederland onder het systeemplafond, Marcel van RoosmalenMeer informatie over buro van Oranje: Buro van Oranje: https://we.tl/t-SZ1HuHsYmw Meer informatie over StoryBrandStoryBrand Podcast https://storybrand.nl/podcast/StoryBrand boek https://storybrand.nl/boek/Private Workshop https://storybrand.nl/home/2 daagse StoryBrand Marketing Workshop https://storybrand.nlStoryBrand Online training https://storybrand.nl/online-training/StoryBrand Gids Certificering https://storybrand.nl/gids-certificering/We horen graag wat je van deze podcast vindt. Laat een review achter op jouw favoriete podcastkanaal.

Yo, Beibi! After taking a short break for Thanksgiving, we're back with a new episode of "The Pan Dulce Life Mixshow" with hosts DJ Refresh and Murcielago Mayor!Returning with a mix this week is our own Captain Panales, DJ Refresh, who throws down 30 minutes of dembow, guaracha, and throwback reggaeton. Catch Refresh live every Friday and Saturday night at Onyx Nightclub in San Diego.And our special guest today is DJ Omix from Houston. His high-energy set consists of Latin-influenced house music, reggaeton, and more! Omix is a member of the renowned LMP crew and is also a mixer on Mega 101 FM on Wednesdays at 12pm and 5pm. He also holds various DJ residencies throughout Texas so make sure to follow him to see where you can watch him live near you!Dale play now y Saca Las Conchas! And make sure to share us with a friend!Visit us for more: www.thepandulcelife.comFollow Refreshwww.instagram.com/djrefreshsdFollow Murcielagowww.instagram.com/14cabezonFollow Omixhttps://linktr.ee/djomixwww.instagram.com/djomix_ See acast.com/privacy for privacy and opt-out information.

Cuma Raporu #179 bölümünde her zaman olduğu gibi Ersin Akman ve Aydoğan Aykanat Türkiye'deki teknoloji gündemi hakkındaki gelişmeleri konuşuyor. Zaman Çizelgesi 00:00 Giriş ve #TemizTwitch 46:32 Yeni IMEI kayıt ücreti 50:14 Sahte IMEI'li kaçak telefonlara operasyon başlatıldı 01:02:50 TOGG hakkındaki gelişmeler 01:13:21 Milli Muharip Uçak'ın (MMU) ilk parçası üretildi 01:17:35 Birleşik Krallık'ta COVID-19 hapı onayı 01:20:50 General Mobile eski yöneticisinden yeni marka: OMIX 01:32:36 Squid Game coini ile 3 milyon dolarlık dolandırıcılık 01:38:51 Facebook yalan haberleri kaldırmıyor

We are back with Episode 46 & this time we bring the one and only DJ Omix from Houston, TX. Non stop reggaetón, dembow, moombahton & more. You already know what to do, HIT PLAY! @DJOmix @DJKiddB #LatinoMusicLab

O 1 de xuño ábrese o prazo de inscrición para anotarse no programa Cuntilín Verán 2021. Este prazo permanecerá aberto ata o 15 de xuño inclusive. O día 18 darase a coñecer o listado de persoas admitidas.Cuntilín Verán está destinado a menores en idade escolar e abarca o período vacacional estival comprendido entre o 23 de xuño e o 7 de setembro de 2021, ambos inclusive, permanecendo aberto todos os días hábiles, de luns a venres en horario de 8:45 a 14:15 nas instalacións do CPI Aurelio Marcelino Rey García, excepto a semana das Festas Patronais de agosto que estará pechado por este motivo.As solicitudes deberán presentarse persoalmente no Rexistro do Concello de Cuntis ou a través da Sede electrónica: https://concellodecuntis.sedelectronica.gal Os impresos pódense recoller persoalmente en horario de mañá, de 9 a 14 horas, na OMIX, no Departamento de Servizos Sociais do concello ou nas Oficinas xerais municipais do mesmo, descargalos directamente da Sede electrónica https://concellodecuntis.sedelectronica.gal/dossier.2 (“catálogo de trámites”), ou escribindo un correo electrónico ao enderezo educacionfamiliar@concellodecuntis.es , solicitando os mesmos. "O Cuntilín é un programa esencial para a conciliación dos veciños/as do concello que Cuntis, é un programa con moita aceptación". "Conchi Campos e José Treviño están traballando na programación cultural dos meses de xuño, xullo e agosto". "Hai que ter moita cautela pero temos que botar a andar e voltar pouco a pouco á normalidade, dende o concello estamos traballando con moita prudencia". Mais información en: Departamento de Igualdade e Benestar Social, telf. 986548005 (ext.1032)/ 986185723 Correo electrónico: educacionfamiliar@concellodecuntis.es PRAZAS LIMITADAS Máis Información CONCELLO DE CUNTIS: ✔️Páxina Web: https://concellodecuntis.org/es-es/ ✔️Facebook: https://www.facebook.com/concellodecvntis/ ✔️YouTube: https://www.youtube.com/channel/UCGA_Z3JwcdMp5iS3UsF6eiw Máis Información TURISMO DE CUNTIS: ✔️Páxina Web: https://turismodecuntis.gal//es-es/ ✔️Facebook: https://www.facebook.com/turismodecvntis ✔️Twitter: https://twitter.com/turismocvntis ✔️Instagram: https://www.instagram.com/turismocvntis/ ✔️YouTube: https://www.youtube.com/channel/UCfZtHlnXSDGunfQGB_p9gOA Máis Información DESTINO CUNTIS: ✔️Facebook: https://www.facebook.com/destinocvntis/?ref=py_c ✔️Twitter: https://twitter.com/destinocvntis?lang=gl ✔️Instagram: https://www.instagram.com/destinocvntis/ ️ "SUSCRÍBETE" ao podcast Máis Información e outras entrevistas: ✔️Facebook: https://www.facebook.com/PabloChichas ✔️Twitter: https://twitter.com/pablochichas ✔️Instagram: https://www.instagram.com/pablochichas/ ✔️Clubhouse: @pablochichas ✔️Twich: https://www.twitch.tv/pablochichas

Hi, I'm Tom Rhoads, CEO of Spencer Health Solutions. Today we have invited Jake LaPorte co-founder and global head of The BIOME by Novartis to return for a second conversation on the People Always, Patients Sometimes podcast. On the previous episode, Jake spoke about The BIOME by Novartis and digital health innovation in clinical trials today, Jake shares his thoughts with our host Janet Kennedy on COVID-19 innovation, digital health, and more. I hope you enjoy their conversation on People Always, Patient Sometimes. Janet Kennedy (00:36): Hi, my name's Janet Kennedy and I am your host for People Always, Patients Sometimes, a production of Spencer Health Solutions. Today we have invited Jake LaPorte to join us again for part two of a podcast episode, where we are discussing The BIOME by Novartis as well as patient centricity in clinical trials. Jake, welcome back to the podcast. Jake LaPorte (00:57): Thank you, Janet. It's great to be back. Janet Kennedy (01:00): So for the folks that might not have caught the previous episode, can you give us your elevator pitch on what The BIOME project is? Jake LaPorte (01:08): I'll do my best. So the thesis behind The BIOME is that Novartis has made a big commitment to become a company powered by data and digital, but yet we're not digitally native. So we almost always rely on an external partner to some extent, to help us build digital solutions. And we recognize we need to get a lot better at partnering with companies in the digital and tech ecosystems. And so The BIOME was developed to break down the natural friction that exists between a large multinational pharmaceutical company and the data and tech ecosystems and help us partner with those companies more effectively to develop digital health solutions that have an impact on patient's lives. Janet Kennedy (01:54): You know, there are a lot - like a lot - of digital tools out there. How do you even sift through and figure out who is a good potential partner? Jake LaPorte (02:04): Yeah, that's a great question, Janet. And that's frankly, what our process is all about, to be honest, because what is not often acknowledged in digital health is there's a scarcity of evidence that is available to understand whether a specific digital solution is going to be scalable if that's even feasible. And that it's going to have a meaningful impact if it is scaled. And so The BIOME is really an evidence generating mechanism so that we can make better more data-driven decisions about how we allocate our resources within Novartis to make sure that we're allocating more resources to those things that are more likely to be successful and have an impact on patient's lives. So for instance, we're doing a lot of work to figure out how we can sift through this complex ecosystem more effectively and more systematically to even surface the right partners. We're doing a lot of work to think about how then we onboard those partners more quickly and how we do what I call healthy proof of concept work with them. So we're really thinking about what are the real meaningful hypotheses, the questions that we really need to answer so that we can get more comfortable, that we need to put more resource behind certain companies and solutions in order to scale them a lot of that discipline. And I think this is true of most of the industry did not exist in the digital space. And frankly, it was a paradox, right? Because we have a very healthy innovation management process when it comes to developing medicines, we certainly just don't plunk a tremendous amount of resource into medicines that haven't gone through certain stages of trials. And we certainly know about our portfolio of trials and allocating resources to those ones that have gone through certain milestones, like stage one, stage two and stage three of clinical trials. However, we weren't doing that as systematically with our digital solutions and The BIOME is really that innovation management process. That's helping us do that with external partners. Janet Kennedy (04:13): All right. So one of the pushbacks that so many young new startups get is how many clinical trials have you done? Well, you know, none because we need you to try us take a risk believe in us. Is that something that's hard to overcome internally? Jake LaPorte (04:33): There are still challenges because there are so many solutions that exist out there. It's impossible for Novartis to make a bet on every company from the very get-go and be the ones that are really sponsoring their initial work. We're trying to make as best decisions as possible. So we spread our bets. So there are some that are kind of very early on companies and we have to do our best to figure out if we believe in what they're doing without the evidence behind them. And that fits well into what we're trying to achieve. And we make a bet on them. There certainly are companies that we do that with there's others, where frankly, we might need to see a little bit more evidence behind them before we make a bigger bet. And so it's a balance that we need to strike as much as we would like to try to support everyone in the very early stages, it's just not feasible for us to do that. Janet Kennedy (05:24): Digital is a pretty broad word. So when you're talking digital, are you literally talking about apps, platforms, medical devices? What kind of things are you looking at? Jake LaPorte (05:35): So for us, we take a fairly loose definition of digital. It could be any and all of those things. Distinctively we don't play in an area where we're partnering with conventional biotechnology partners to, for instance, co-develop assets or license, an asset from them. That's a clear place that we play, but any where there is data to be generated or devices to be tinkered with. I think that's a natural area where the bio model that we developed can be very effective. Janet Kennedy (06:11): Before we jump into the bigger conversation, can you remind folks how they can find out more about The BIOME? Jake LaPorte (06:17): Sure. They could probably Google Novartis BIOME, and we have a page that will give you a little bit more information about what The BIOME is, give you links to some of the leadership team, and you can always feel free to reach out to me or others to get more information. Janet Kennedy (06:36): Alright. And we will include a link to that in the show notes. Jake LaPorte (06:39): Perfect. Janet Kennedy (06:40): So Jake, one of the things that I was very curious about is the sea change that has happened and we're golly, nine months into a COVID process. How has The BIOME changed from this time last year? Jake LaPorte (06:57): It's been a meaningful change, not so much to the operating model that we developed, because we think that's a good one for us to facilitate digital innovation and meaningful partnerships to create digital solutions that have an impact. But certainly when you factor in COVID-19, which is first and foremost, a human tragedy, it's also certainly surfaced some of the challenges of the healthcare ecosystem. And we have really focused on helping develop solutions that solve some of the challenges presented by COVID-19. So for instance, we have a big initiative as a company on helping to think about developing telemedicine solutions that improve the continuity of care for folks that now cannot necessarily set up regular doctor's appointments, right? So there's a whole second level issue occurring in healthcare, which is that people that normally should be going to the doctor and getting diagnosed with other diseases, simply aren't going to the doctor or their physician as much and are suffering from diseases that they normally wouldn't have suffered from. So how do we help patients and physicians connect more effectively? So we're working a lot on solutions like that, making them scalable and effective and providing more convenience to patients and physicians that are challenged in this new era. We're also re-diverting some of our resources to focus on specific COVID 19 challenges that have been posed by certain government. So for instance, we have a BIOME in the UK located in London and they work with the NHS and the NHS has defined some specific challenges that they wanted to try and solve. And so our entire innovation program that we have in the UK this year was diverted to helping solve some of the challenges that the NHS has presented. So I think COVID-19 has given us a new problem set if you will, to focus on. And it certainly accelerated a lot of people to really think about how to use digital solutions creatively to overcome some of these challenges. Janet Kennedy (09:20): Well, I think that's really exciting because in many cases we think about pharma as being the big engine. That's only rolling forward at a certain pace and suddenly the flywheel of COVID-19 has accelerated that. And I think it might be really exciting to be working in a company to know that this is not a solution five years down the road. We're solving something today. Jake LaPorte (09:45): Yeah, certainly. I think again, although it's first and foremost, a human tragedy, it's sad that this is the catalyst behind some of this digital transformation. I think the solutions that are being developed are solving some more fundamental challenges in healthcare that will have longer term benefits after we get to a better place with COVID-19. Janet Kennedy (10:05): I agree. Totally. And I think telemedicine, which has been in development for over 20 years is finally seeing its day. Do you see any other type of digital health solutions that we're going to be treating more as an everyday use that might not have been accelerated so quickly? Jake LaPorte (10:25): Yes, certainly the biggie out there is telemedicine, as you already alluded to Janet. But I think that frankly opens up a platform for a lot of other digital solutions to be incorporated into a telemedicine backbone. I think as telemedicine gets more widely adopted it's, there will be ecosystems of digital devices that collected data that can be used in a telemedicine forum to make better more data-driven decisions by a physician remotely. I think you'll see these ecosystems of devices spring up that are expressly designed to fit within telemedicine scenarios. So almost like a virtual checkup room, for instance, that the doctor can use to deliver care more effectively. And in remote scenarios, I think we'll also see more creative ways to do digital clinical trials. For instance, I think we'll be using data more often as telemedicine kind of increases. So does the data that's being collected. And as the data improves that we have on patients, the smarter we can be around developing hypotheses for clinical trials that make them more honed and more focused on answering the questions we need to answer and nothing more than that. So I think we'll see trials get more effective. So I think there will be a number of knock on effects that we'll see as this increase happens. Janet Kennedy (11:55): Do you see personalized medicine becoming something much more central to our healthcare system? Jake LaPorte (12:01): Certainly over time. You know, I think there'll be a certain amount of catalytic event that happens through COVID-19 with personalized medicine. But I think that will generally occur over time with more development. One of the things with personalized medicine is that we've often looked at what we've can do on the molecular level with the evolution of Omix. And we've seen that as a flagship for what we're going to be able to do with personalized medicine, but the conversation is often not focused on the other part of personalized medicine. What we really need is that really well, curated longitudinal data set of healthcare outcomes across a population that allows us to really link up what it means on the molecular level, to what it means for healthcare outcomes. And I think once we start getting these more curated longitudinal healthcare outcomes, datasets, possibly through digital technologies and starting to make those links back to the Omix, we'll be able to make greater strides in personalized medicine. So I'm very optimistic about the future of personalized medicine. I don't know if COVID 19 per se is going to accelerate a lot of that right now. Janet Kennedy (13:17): Alright, now understand that I'm speaking to a PhD in chemistry, which is not the degree that I have. So I'm going to ask a little bit of a 101 level question here. When you talk about getting more data, are you looking at beyond adherence and persistence? This is really digging a little bit deeper and how can patients be involved in providing that kind of information? Jake LaPorte (13:41): So if I relate it back to the question posed around personalized medicine, I think, again, this is something where the healthcare community could really come together and make great strides in how we advance personalized medicine. So personalized medicine has been a concept that's been around almost since we started the human genome project, right? The aspiration of course, is that we can deliver therapeutics and interventions that are personalized to a person's genetic makeup. But what we've realized over time is that we need more information to really interpret different gene sequences that people have and be able to better predict what that actually means for their health and how they will actually experience a particular therapeutic or intervention. And then more over, we have to also incorporate environmental effects that those people experience because different environmental effects obviously have different impacts on patient's health. So therefore the grand challenge, I think in personal health is to create a large dataset across a wide population of folks that is able to basically detail what their health care experience and outcomes have been over a long period of time, as well as their genetic makeup and their proteomic signatures and sequences to them be able to make that Rosetta stone translation, if you will, between certain sequences of DNA that might exist with one person and not the other, certain protein expressions at one person as versus the other, certain environmental effects that a person experiences versus the other, and then say, Oh, this is what that means in terms of how their health care and their outcomes have been. Right. And so this is where actually patients can make a tremendous contribution, right? And the amazing thing about it is there's long been this concern about privacy, right, privacy, around the types of data people are sharing. And that is a very big concern and people are very right to have that. But now with the advent of some of these newer technology paradigms, like blockchain technology, and distributed ledgers, there now becomes an opportunity for patients to own their data, their healthcare data, and share what they want when they want with whom they want and revoke access when they want. And not only that, it then becomes possible for this learning technique machine learning technique called federated learning, which allows you to kind of anonymously sample data from patients that may be on part of a distributed ledger and not have to take a lot of their personal healthcare information, but just take the information they've generated health and therefore anonymize that, and still be as effective in developing new, more sophisticated algorithms. So again, this is more of a grand challenge, but I think it's something that the community is the answer is how do we develop technology platforms that allow patients to be involved in contributing data throughout their lifetime, in a safe and effective way where they're recognized for their contribution, right? Cause that's another piece of it. They need to be recognized for the contribution that they're making, but it allows us to advance medicine and ultimately get better at treating people. Janet Kennedy (17:14): In the rare disease community - and I am not familiar with everything you all are developing - but are you working in rare diseases at all? Jake LaPorte (17:21): So we don't have a big focus on rare diseases per se. I think what you'll find is we work in rare diseases in a targeted way, and it's more platform driven. Like we have a cell and gene therapy business unit. And so one of our major products that we just got approved last year is Zolgensma, which is a gene therapy to treat spinal muscular atrophy - SMA - it's miracle, right? Because if you are able to get a treatment to a patient within a certain amount of time, it pretty much cures them from a disease where they would definitely die. So we work in rare disease, but we don't have like a rare disease business unit per se. Janet Kennedy (18:02): So one of the things that we're hearing from people who have COVID-19 is there long-term health concerns that may be a result, whether it's heart impact on lungs, et cetera. So co-morbidities become a much more important part of understanding how the data works together and then it gets really complex. So are you finding in The BIOME or in the industry at large, this awareness of the importance of pulling together very disparate pieces of data to try and understand health issues? Jake LaPorte (18:34): Yeah, so I think this conversation is starting to become more prominent throughout the entire healthcare sector. The understanding that we need to be able to have more datasets, talk to each other and be joined together in order to power things like machine learning and AI, right. We often talk a lot about the promise of AI and machine learning in healthcare. And it turns out that one of the biggest barriers to seeing more impact from this very impressive technology paradigm is just being able to have the structured datasets to train these algorithms. And so I think there's more recognition that number one, the healthcare data that we do have tends to be very fragmented and incomplete and that we need to as a community come together and be able to do something about that. So what that means is we need to come together and develop data standards and an ontology, which is basically a language or a way to relate data sets together in order to join datasets that we already have. And then in the future, we need to think about ways in order to collect data more effectively to sort of power some of these powerful technology paradigms like AI and ML. Janet Kennedy (19:54): And I think as you said earlier, digital health literacy is essential. Helping patients understand that their data is really needed to help themselves and others. Jake LaPorte (20:05): That's exactly right. It really boils down to ultimately increasing digital literacy, but also developing solutions that make sense, right? So I think we need to be very focused on the patient, what their problem is, how do we solve that problem and how do we protect their privacy? And then how do we communicate that to them to help them understand that that's what we're trying to do. Janet Kennedy (20:30): Well, and that's what should always be right? Focused on the patient for the patient, because that's what we're trying to do. Jake LaPorte (20:36): Exactly. Janet Kennedy (20:37): Well, Jake, what a fascinating conversation. And I appreciate your spending the extra time to do a part two episode of our conversation. I appreciate your being here very much. Jake LaPorte (20:48): My pleasure, it was fantastic conversation for me and I hope you and the audience enjoys it. And again, if there is any questions about the bio that folks want to follow up, please feel free to do so. Janet Kennedy (20:58): Thank you for downloading this episode of People Always, Patients Sometimes if you enjoyed our conversation, a review and a rating on iTunes will help us find more listeners. This podcast is a production of Spencer Health Solutions.

This week’s episode is special: we have the former and current Editors-in-Chief of Circulation on Circulation on the Run. Join Dr Amit Khera, Digital Strategies Editor of Circulation, as he speaks with Dr James T. Willerson, Editor-in-Chief from 1993 to 2004; Dr Joseph Loscalzo, Editor-in-Chief from 2004 to 2016; and Dr Joseph A. Hill, the current Editor-in-Chief. They will discuss the history of Circulation and how it continues to evolve. TRANSCRIPT Dr Amit Khera: Hi, this is Amit Khera. I'm digital strategies editor for Circulation from UT Southwestern Medical Center in Dallas. Today we have a very special Circulation on the Run. We have three Editors-in-Chief from Circulation. First, we have Dr James Willerson, who was the Editor-in-Chief from 1993 to 2004. He's a President Emeritus at the Texas Heart Institute. We also have Dr Joseph Loscalzo, who was Editor-in-Chief from 2004 to 2016, the Chairman of Department of Medicine from Brigham and Women's Hospital. And finally, Dr Joseph Hill, the current Editor-in-Chief, the Chief of Cardiology at UT Southwestern Medical Center. Welcome, gentlemen. Dr Joseph Hill: Thank you. Dr James Willerson: Thank you. Dr Joseph Loscalzo: Thank you. Dr Amit Khera: Dr Willerson, I must say, looking over the tenure prior to Dr Loscalzo, you had one of the longest tenures ever as Editor-in-Chief of Circulation, and certainly a lot happened in the practice of cardiology during that period. It was a really formative period in cardiology. As you think back, what were some of the most important topics that you covered during that time as Editor-in-Chief, thinking about the evolution of cardiovascular care and science at that time? Dr James Willerson: You have to remember, there have been many editors at Circulation. We all build on the shoulders of others, certainly I did. I really wanted Circulation to be the premier cardiovascular journal in the world. I wanted it to be much like the New England Journal of Medicine, but the New England Journal of Medicine Circulation of Cardiology. I wanted to publish it every week. We got permission to do that. That wasn't easy, but we were fortunate. I've been accused of wanting to publish it every day. There's actually some truth to that. I didn't make that. I didn't try very hard. I wanted to be able to present the information, important information, to everybody who cared about cardiovascular medicine: physicians, scientists, students, nurses, those who cared for people, and I wanted to do it frequently. I wanted to publish it quickly. So, we had some success with that. There are many other things that are well-known to the other editors, all of whom have built before me and after me, and I'm very proud of them. Dr Amit Khera: Well, thanks for that. And certainly, as you pointed out, this has been an evolution where you took the gauntlet, if you will, from the people before you, and then built on that and had many advances. I guess after you, Dr Loscalzo, you I think did have the longest tenure if I saw of any of the editors and similarly, a lot of evolutions in cardiovascular care and a lot in science, particularly during your time. Tell us a little bit about any particular papers or topics that you focused on, or that really were revolutionary in the cardiovascular space during your tenure. Dr Joseph Loscalzo: I'll pick up where Jim left off and just make the case that as you're suggesting, I mean, there's sort of been a natural transition of the kind of science that Circulation has been publishing over the tenure of the three editors here today. Before Dr Willerson, it was largely physiology and excellent clinical science. Jim really expanded the scope of what Circulation published to begin to put in press in its pages, fairly basic and translational science as well. I picked up from what he'd laid the groundwork for to expand the scope of that science. And as you know, expand it to the point that we had to develop daughter journals that would pick up the mantle in each of these increasingly subspecialized areas. So, it's hard to think about those papers that I found have the greatest impact because every field had several of them in my several years as editor. As you know, the subspecialty journals that we established, which remain active to the current time, are also broad in their scope from outcomes based research to genomics and proteomics insistence, cardiovascular medicine, to everything in between, imaging, intervention, heart failure, and electrophysiology to arrhythmias. Each of these was led, and continues to be led, by outstanding leaders in their subspecialty fields. I think the beauty of Circulation in contrast to even fine journals like the New England Journal of Medicine, is that Circulation has been able to put on its pages those studies that really do span quite a spectrum. We don't shy away from very basic studies. That actually began with Jim, I must say, because that wasn't the case previously. And of course, we move right through to epidemiology and outcomes based research. And the impacts have been broad in each of those fields, as witnessed by the excitement and uptake of the journal, measured however you wish, by impact factor, or citations, or the frequency with which it's referred to in the lay press. So, I think that tradition certainly continues under the current editor with papers of extraordinary impact. Dr Amit Khera: Thanks for that. I think your point about the evolution of science over time from Dr Willerson and certainly during your tenure and beyond to the breadth of Circulation currently. You also touched on the subspecialty journals. That happened in your watch and that was quite a marked change in cardiovascular medicine to have that explosion of new journals, if you will. What do you think the impact of those subspecialty journals has been for the cardiovascular field? Dr Joseph Loscalzo: We struggled with the idea about whether or not we should pursue that kind of fragmentation. What really pushed us was the fact that the acceptance rate remains quite low, in those days, probably eight or so percent range at its nadir. So, we were rejecting a lot of really excellent papers which wound up in competitor journal pages, that we would like to have accepted and been given the scrutiny of the careful reviews and editorials that accompany papers accepted by Circulation. We felt the best way to do that under the circumstances was to create these daughter journals. They succeeded, in many respects, beyond our wildest imagination. The numbers of papers that were published in the family increased, I think in the first two or three years, by at least 2-to 3000. So, that really speaks to the fact that we kept the best papers in the family. We gave them the right kind of audience. Some of these would have been too technical or too highly specialized to have been published in Circulation proper, but certainly of the highest quality and of significant relevance to the subspecialist. So, we think that it was a successful experiment. Now it's sort of become tradition. I think that the question that will always come up, of course, is can we fragment things more? I would say one of the best reasons to make the case that this was a successful experiment is that if imitation's the sincerest form of flattery, the New England Journal is now going to start three subspecialty journals. In fact, in my role now as an editor of the New England Journal, editor-at-large, they asked my input in how to design those daughter journals and what to expect from them. Dr Amit Khera: Well, I think that's a great point. It certainly has been a resounding success and as you pointed out, imitation is the best form of flattery. I'm going to pivot now to Joe Hill. Dr Hill, you have certainly been the beneficiary of all the great work that these two editors have done in the past. You've inherited a very successful journal and also have crafted your own vision for where you want Circulation to go in your mark. Tell us a little bit about some of the new initiatives you've tried to implement, leveraging on these past successes. Dr Joseph Hill: Thank you, Amit, it's an honor and a privilege to be in this conversation, frankly. I mean, Dr Willerson made this a weekly journal. That was back in the day when FedExes were flying around. Everything was paper. That kind of volume with that technology is impressive. And Dr Loscalzo, who has been a friend and mentor for many, many years, spearheaded the subspecialty journals, as we just heard, and took the journal to yet new heights. Each of you has been a pioneer and we've been fortunate to put together a team that I think has moved in exciting directions. We've leveraged technology now, such that we have our video conference meetings. We meet in a video conference with editors from 17 different countries. We have a third of our editors in Dallas, where I live, a third in the US outside of Dallas, and another third in 16 other countries. It turns out we alternate the time of that meeting each week because there's no single hour of the day that works around the globe, so we move it around to capture Asia or to capture California in alternating weeks. That has been a thrill and, honestly, I believe a robust success. We have leaders on the ground in all these different countries. We have a highly diverse team across the different subspecialty domains of cardiology, across different geographic regions, across race and sex and gender lines. It is an amazing team. And Amit, who leads our robust digital efforts, including this podcast and our efforts on social media, again, the opportunity now in the 21st century to take these initiatives forward has been a real privilege. Dr Amit Khera: It's ironic that Circulation was doing Zoom before everybody else was in the modern era. I'm going to pivot back to Dr Willerson. As Dr Hill just mentioned during your tenure how the volume of papers was handled, FedEx and sort of the nature of the journal publishing process. And now in the modern era, we have so much different information. We have a huge volume of journals. We have online, we have Twitter, we have podcasts. We have people that are consuming information in so many different ways. Tell us from your perspective, what's the role of the scientific journal currently and how has it changed at all in the last few decades? Dr James Willerson: It's always going to continue to evolve. It's about as good as it can be right now with Dr Loscalzo and Dr Hill's leadership, and I'm really proud of them. There'll be more. We can't even imagine what it will be in two or three years. Of course, it'll be better and better, faster, almost momentary. Thank you, Dr Hill. Dr Amit Khera: Thank you for that. I think we all look forward to seeing how this evolves more rapid information, rapid turnaround. I'm certain that will change. Dr Hill, you had a comment on that? Dr Joseph Hill: We live in an era now where peer review is under attack in many ways and pre-print journals, blogs and so forth. And one of the things that I've really seen, and we've all seen, is how the peer review process, and we're all authors, right, we live on the other end of that stick, but it really is important. It makes a big difference. And people who are anxious to accelerate that process, I totally get it. We work very hard to do that. At the same time we, following the traditions here, have an intentionally redundant review process where every paper is evaluated by multiple editors and multiple peer reviewers. On a number of occasions, we've avoided a pothole, or we've improved a paper many, many times. And that is something that has really been impressed on me that I think people who aren't on this side of the editorial fence might not appreciate as much. Dr Amit Khera: I think that's an important point about sort of the rigor about the way that articles come out in Circulation. And Dr Loscalzo, maybe as an extension of the last question, what do you see as some of the challenges going forward or opportunities for Circulation? You think about where it's been, but what are some of the things that you look forward to for Circulation in the future and what are some of the things you're concerned about? Dr Joseph Loscalzo: Well, I too am concerned about this issue of peer review being under attack, and I'm particularly concerned about it for papers that have direct clinical impact. A good example of that concern, of course, are papers published, or at least publicly released, on non-peer reviewed websites like the archive sites because of their importance in the COVID epidemic, potentially. We all know of cases of drugs, at least in test tubes, with cultured cells and viruses appear to be effective that have adverse clinical consequences. So that, and more than in any other sphere of science, ensuring that proper peer review from as many perspectives as possible is always a part of the process is absolutely critical for clinical medicine. And to me, the threat that this need for acceleration and rapid peer review poses and the sort of socialization of the transmission of scientific information that we're all interested in doing really has to have the brakes put on it a bit for the clinical science that the journal represents for this very important reason. Not to say we want to slow things down, we want to make sure that the best possible reviews are performed before we release it to the public. I know that, as Joe was pointing out, one of the most exciting parts of the role of when I led the journal was the weekly meeting. We had a face-to-face meeting because all of our associate editors, save one, was actually physically proximate and they could travel to our conference room. But it's a wonderful exercise to have people of very different perspectives, from basic scientists, to clinical electrophysiologists, to outcomes researchers, make comments on papers that were completely outside their sphere. The argument, of course, is if one can write and transmit a thought with the clear intent in a way that's rigorous and logical, that any reasonably bright person with reasonable scientific background should be able to understand it. And often these folks with very different scientific backgrounds have perspectives that very clearly improved the paper when they were acted upon. That's a process that doesn't exist in many other journals, I have to say. And I would encourage Joe, which I know, well, he's doing this because he enjoys it and he recognizes its importance, and Joe's successors continue to do that as well because that will ensure the value of the journal through all of the challenges that it is going to have to face in the next decade or two. Dr Amit Khera: I think that was a great point. We're certainly seeing candy bowl examples of the importance of this rigorous process of the editors looking through it carefully and, as you both mentioned, peer review. Joe Hill, I'm going to let you maybe have the last word. I know how hard the three of you have historically worked on your craft for the journal, how much effort you've put in, but I also know it's quite a rewarding job. What would you see as the best part of being Editor-in-Chief of Circulation? Dr Joseph Hill: Oh my, I'm learning something every day. I've been on about a steep a learning curve as when I was an intern at Dr Loscalzo's hospital long ago. Under Dr Willerson's term, I imagine many, many studies came in on acute coronary syndromes and thrombolytic therapy, primary PCI, antiarrhythmic drugs. We haven't seen an antiarrhythmic drug paper except for a recent review we did, but for quite a long time. It's artificial intelligence, it's big data, it's the UK Biobank, it's Omix, it's incredibly sophisticated genetics and genomics and basic science with genetic manipulations, IPS cells. It's a very different world now than it was 10 years ago, 20 years ago and it certainly will be again, 10 and 20 years down the road. We are now approaching, I will say, 600 COVID related papers, and they're still coming in at a record pace. The world has changed. As I said before, this is the 70th anniversary of this storied journal. And it is truly my honor to be able to stand on the shoulders of Doctors Loscalzo and Willerson. Dr Amit Khera: Thank you. I think that's a great way to end this podcast and congratulations on the 70th anniversary. It truly has been a privilege to chat with the three of you today. I want to thank you not only for what you've done for Circulation, but for the field of cardiovascular medicine. This is Amit Khera, digital strategies editor for Circulation. Next week we're back to our usual podcast with Carolyn Lam and Greg Hundley. Take care. Dr Greg Hundley: This program is copyright the American Heart Association, 2020.  

Boomer Anderson hails from the USA but has lived and worked in many countries and cities from Wall St to Singapore to Amsterdam among others. After graduating from the University of Minnesota, Boomer pursued his first love (finance) through a successful career in investment banking in New York and Singapore. Always desiring to learn more and pursue his second love (health), Boomer left finance to found a successful clinical practice leveraging data to help entrepreneurs and executives achieve better performance through health. He continues to pursue his joint loves of health and finance through early-stage startup investments, advisory roles, and public speaking. In his free time, Boomer enjoys experimenting with the latest in performance technologies, travel, adventure, and spending time with his girlfriend. He had a  fast-paced career in investment banking and venture capital. Helping countries and companies raise funding. He lived life in the extreme both in the high flying career world and in his sporting endeavors, doing an extreme amount of traveling and long days and living on very little sleep thinking he was bulletproof until a serious heart condition stopped him in his tracks at age 30.   Since then he pivoted and in his quest to heal himself has become over the years an expert in health optimization, biohacking, data tracking in relation to health and much more. He shares his deep insights into the exciting world of the quantified self, the power of data and testing for health and the change in paradigm that is happening in the world on biotech. Boomer is also a podcaster and has a top 100 rated show many countries. His show is Decoding Superhuman and you can reach out to Boomer at www.decodingsuperhuman.com and follow him on instagram and facebook.   He is also partner in Dr Ted Achacoso's www.homehope.org which is a complete new system looking at the holobiont and metbolome for health optimisation.     We would like to thank our sponsors for this show:   www.vielight.com   Makers of Photobiomodulation devices that stimulate the brains mitocondria, the power houses of your brains energy, through infrared light to optimise your brain function.  To get 10% off your order use the code: TAMATI at www.vielight.com     For more information on Lisa Tamati's programs, books and documentaries please visit www.lisatamati.com    For Lisa's online run training coaching go to https://www.lisatamati.com/page/runningpage/ Join hundreds of athletes from all over the world and all levels smashing their running goals while staying healthy in mind and body.   Lisa's Epigenetics Testing Program https://www.lisatamati.com/page/epigenetics/ Get The User Manual For Your Specific Genes Which foods should you eat, and which ones should you avoid? When, and how often should you be eating? What type of exercise does your body respond best to, and when is it best to exercise? Discover the social interactions that will energize you and uncover your natural gifts and talents. These are just some of the questions you'll uncover the answers to in the Lisa Tamati Epigenetics Testing Program along with many others. There's a good reason why epigenetics is being hailed as the "future of personalized health", as it unlocks the user manual you'll wish you'd been born with!  No more guesswork. The program, developed by an international team of independent doctors, researchers, and technology programmers for over 15 years, uses a powerful epigenetics analysis platform informed by 100% evidenced-based medical research. The platform uses over 500 algorithms and 10,000 data points per user, to analyze body measurement and lifestyle stress data, that can all be captured from the comfort of your own home   For Lisa's Mental Toughness online course visit:  https://www.lisatamati.com/page/mindsetuniversity/ Develop mental strength, emotional resilience, leadership skills and a never quit mentality - Helping you to reach your full potential and break free of those limiting beliefs.    For Lisa's free weekly Podcast "Pushing the Limits" subscribe on iTunes or your favorite podcast app or visit the website  https://www.lisatamati.com/page/podcast/   Transcript of the Podcast:    Speaker 1: (00:01) Welcome to pushing the limits, the show that helps you reach your full potential with your host, Lisa [inaudible], brought to you by Lisatamati.com Speaker 2: (00:13) Once again to pushing the limits before we get underway with this week's very special guests. Just like to remind you, if you don't mind doing me a big favor and giving this podcast or writing a review on iTunes, that would be hugely, hugely helpful and helps us show where the ratings and exposure so we get exposed to more people and more listeners so we can get our message out there. So really, really appreciate your help. If you want help also with your running or with your health optimization or you want help with mental toughness coaching, check out all our flagship programs over at Lisatamati.com. Hit the programs button and you'll be able to find out all about our running hot coaching, our epigenetics in the mental toughness mindset you e-course right now. Today's guest is sitting in Amsterdam and he is an incredible person who has a background actually in investment banking and finance. But has now done a completely one 80 pivot into health optimization. Someone who has a, she has a lot of interests with what I do, and I know you're going to get a huge amount of value out of this interview. So without further ado, over to boomer Anderson. Speaker 3: (01:25) Well, everybody needs to tell me to here and welcome back once again to pushing the limits. It's fantastic to have you with us again. I'm super excited for today's interview. I have a very, very special guest who is the host of something called a podcast called decoding superhuman. And you guys have to check this out. This gentleman is sitting in Amsterdam, which is a first for me. I haven't had anyone from my son's name. He's actually so welcome to the show boomer Anderson. Welcome. I'd really Speaker 4: (01:54) Release a thank you for having me. This is an absolute pleasure. Speaker 3: (01:58) Oh, it's so cool to have you. So boomer and I have connected other, the love for podcasting really and through an audio engineer of all things, Roy Roy, Roy helped me and taught me. And Burma is, it does stuff that's right up my alley. So very much a expert on human performance and in many seats is other word. And his, a podcast as a seed called decoding superhuman and has a very interesting backstory as well. So boomer, let's start with a little bit about we from who you are and your you know, your, your career before you got into this. Speaker 4: (02:40) Oh, how long did we actually have here? So let's start with the beginning, right. And then, because you mentioned that I love all things performance just like you do. And that's absolutely the truth. And it started from a very young age, you know, growing up I had the benefits of the son of a yoga teacher on one side and then a finance professional on the other. So I had this kind of eats me at East meets West growing up experience. And you know, I was been obsessed with performance from a young age, whether it was academics or athletics, it was always, how do you push it to that next level. We can talk about it later, but sometimes that hurts when you push it to the next level. Speaker 4: (03:25) And you know, that next level led me to go to college in Minnesota and then eventually work on wall street after two years in New York and I, I was in New York at times that people don't want to be in New York. Right? Like my first day on wall street was the day that Lehman brothers filed for bankruptcy and AIG gets nationalized. Oh my gosh. Hell of a first day. Right. And so my career path kind of changed forever. And after two years I've moved to Singapore where at a very young age I became the head of a, a deck capital market stuff covering South Asia. And so my responsibility was 14 different countries helping companies and governments raise money across the world. Yeah. That all sounds amazing and glamorous. And I had the pleasure of traveling to 40 countries over the course of four years, basically living on a plane. Speaker 4: (04:19) And that entire time I thought I was healthy. Right. Because if you read men's health, have you read whatever it is, whatever those fitness magazines are, they tell you that diet and exercise are all that really matters. And you know, I was one of these guys who not following whatever the diet your was, I've probably tried them all with the exception of maybe being vegan. And then I was also very into a sport called CrossFit. And I pushed, I know there's a very, there's a very strong theme that I think reverberates in both of our lives is that I pushed everything to the extreme, whether that be work, whether that be play, whether that be exercise. And so, you know, I was the guy who was like, I'm going to work this investment banking career, get you know, from the age of 18 to 30 is getting four to six hours of sleep per night. Speaker 4: (05:10) And I'm going to try and work out like rich Froning because I had a goal of beating rich Froning and the CrossFit games delusional goal, but it was a goal. And so, you know, go bigger, go home. Right? And so this eventually has a wall that I hit, but I've had, and we can talk about that wall here in a second, but there's this constant reverberating theme of trying to elevate performance. I now consider it my mission in life to elevate the human experience through health. And I look at that through a number of different lenses and a result of the learnings on the journey, so to speak come up with a fairly elegant system in order to help others do this. Wow, Speaker 3: (05:58) That's a, that's a nutshell. A pretty amazing life. So investment banker in the finance world, I mean, that's a dream for many young people to get into that, that world was, is just idea for us. A short second. Did that burn the hell out of you? You know, physically, obviously traveling all the time, but also the meeting side and the pressure in that game. Speaker 4: (06:23) Sure. So let's talk about that because most of the rumors you hear about investment banking or Kennedy true. When I started in investment banking, I lived mainly in the office. And frankly that changed over time. But it was more, I lived with a cell phone instead of in the office. And you know, I've spent many a night where it was okay, you worked the entire night, go home, change your clothes and come back into work the next morning. I've slept in a desk. I've done many times where I've gone into this is actually embarrassing Lisa, and I can't believe I'm telling you this story. But like I went into, I went into the bathroom, put my legs up and fell asleep to get 20 minutes of sleep. Right? And so just like in those kind of extremes produce extreme results. And so you know, you, he pushed your body to the limits. Speaker 4: (07:19) And of course as you get more and more senior, there's the stress of you have to meet a budget, you have to worry about a coworker stabbing you in the back. All of these things. But the experience itself of, and I was helping companies and governments raise money and experience of itself, of being able to look at how a country funds itself and saying like, Hey, I had an impact on that. And there's one or two countries that I can point to and say I had a significant impact on how they fund themselves even till today is pretty rewarding. But yeah, the stress is ridiculous. And so let's talk about some of the warning signs, so to speak. Right. And so one of those warning signs I collapsed in my shower just from exhaustion. I've been to the hospital more than once for exhaustion. Speaker 4: (08:11) I've had parasites. I was traveling to places like India, Bangladesh, all these things, parasites. I was vomiting. I was, you know, falling asleep at my desk. All of this stuff. I was doing three, four and a half hour red eyes from DACA and going into the office the next day. All of these things you can add, you can look at it and say like, Hey, any, any person with any reasonable level of intelligence could have looked at this from afar and said, at some point this kid is going to go head first into a wall. But that kid wasn't willing to admit it. Yeah. Speaker 3: (08:48) Well you live in, you live in that world where it's expected, this hard performance is, you know, 24, seven, the labels of your anxiety must've terrific. Speaker 4: (09:00) Terrific. Yeah. And I've you know, it's something that I talk about openly now and it took me awhile to talk about it openly, but I've had issues with panic attacks you know, getting in front of people and you know, starting to sweat for no apparent reason. Just extreme nerves at an occasion. And then when you start breaking your circadian rhythm, cause I was traveling time zones all the time, right? Like I was doing, I went to Europe one year, 18 times from Singapore. So that's that's already a six to seven hour time change. I went to from Asia to the U S six to seven times in one year as well. And so you're talking about like my circadian rhythm was not existing. And so like I developed social anxiety, I developed anxiety around people and it just became this one big ball of anxiety. Speaker 4: (09:52) And you just kind of look at different ways to deal with it. You know, at that point I was self-medicating mainly through alcohol, but it's so medicated through alcohol and CrossFit, you know, I was just looking for anything to escape. Right. And, and so like, I had this brilliant job and I, I don't think I appreciated it at the time, but I got this brilliant job and I was like just stressed. And you know, there were times when I was younger in New York where I just walked down on the street and pray that like a taxi cab would hit me because I would get some sleep in a hospital. Right. And it's just, yeah, I guess to answer your question, yes, Speaker 3: (10:34) It's a little bit stressful. It's a little bit stressful and to show up and, you know approach you for being open about this because this is the, this is what my podcast is known for and we tell the real shit here and we died and I've had panic attacks, I've had anxiety, I've had depression, I've, you know, been in shitty relationships. I've lost all my money and revoke myself. I've, you know, I've been there and the people know that the dramas that I've gone through, and I think the power lies when you share those shitty moments and you share the difficulties that you went through because the learning is in the air for the people that are listening that we have really can shortcut the people, you know, not repeating the same problems to go. That is the whole point. And to, to be able to you know, withstand that huge amount of pressure and to, to live at that high performance level. And I totally get your mentality of, you know, go hard and go home and extreme and and when you're young, you're Bulletproof, you're Bulletproof and nothing can break me. But I know in your story that came to a crushing sort of how to, at some stage it's go into that story a little bit. Speaker 4: (11:47) Yeah. So the silver bullet, so to speak, came shortly after my 30th birthday and I was one of these people. So for a very long time we were talking about how I grew up kind of East meets West and realize that health had a, an input in this idea of performance, particularly workplace performance. And I'm pretty nerdy when it comes to data. And so I actually calculated what was my return on health investment. So I would invest X amount in health per year and would get X amount growth in my bonus, so to speak. It wasn't a direct correlation, but it was just a way to justify what I was spending on these things. And I, you know, I'll caveat this by saying I wasn't necessarily spending it in the right way. I was spending on things that like Tim Ferris recommended or whoever, Dave Asprey in those days, actually it was the early days of day out. Speaker 4: (12:38) And Dave asked for even before them and as a part of this little esoteric forum on the internet called quantified self. And so I became very interested in the idea of if I monitor this data point about myself and it can be subjective or it could be something like my aura ring that I'm wearing now, you know, how do I take that information and apply it to perform better in my life? And again, for a long time I wasn't doing this in the right way. And so, you know, I was spending all this money and for my 30th birthday I was on the verge of resigning at this point from my job because you know, I done already gotten so much in investment banking and at that point everybody is quitting to build apps. And I was just like, I'm going to build an app. Speaker 4: (13:25) I didn't really have a good idea, but like I'm going to build an app. And so in the process of resigning, I went in and got all of these tests and one of those tests was actually calcium score and the calcium came back as positive. Now, as a 30 year old having calcium in your heart, I was at a 95% risk of a cardiac event. And so I had a blockage of my left anterior descending artery. Like any person who gets diagnosed with heart disease, what do they do? They give you a Staton? Well, the Staten induced chest pain so much so that I could barely walk down. If you're familiar with Singapore, there's this area called call your key and it's basically you go from Tanjong pagar over to my office and I was walking down that street and like gripping my chest in pain. Speaker 4: (14:15) And I said to the cardiologist at the time, you know, Hey, I think this has something to do with this stat. And he said, no, and you know, I don't fault him at this point because the education wasn't necessarily there, but now there are genetics that are associated with stat and the do chest pain. So I'd take, I stopped taking this, the Staton because it wasn't really a cholesterol issue in the first place. And really the pain went away. And so that was kind of the aha moment. Like, Hey, there's this data out there and I had it from my 23 and me test. That's not an advertisement for 23 meters. It was just like the easiest just to give them time. And I realized like, Hey, what else can I do with this stuff? And that was kind of how I went from, well there's a whole journey there on how do I make sure I don't die. But also as I was making sure I don't die, people were like, Hey, this is interesting. Can you do it for me? And that was really what became my, my transition. Speaker 3: (15:22) Wow. And now this is so interesting cause isn't it funny when you have either a personal evangelism, not my case with my, my family and my mum. That it just totally changes your, the lens that you're looking through. And as in you have a huge intimate thank you. That's very kind of listen to your podcast, but you have to have a huge intellect, you know, and I'm struggling half the time to keep up. But anyway. So you've taken that huge intellect that you applied, excuse me, to the finance world and you've gone, even though you're not a doctor or anything like that, you've gone into plot all that data and that ability to analyze data across into a new world now, which is what I find fascinating that you've made this transition and I've seen a number of other professionals through this as well who have suddenly gone into the world of health and understanding that the knowledge is now, you know, coming and out there and the, you've, you've gone across from the investment side now into the health side and quantifying it all and using data and using genetics and using all the other tools to now actually helping people with their health, then there'd be a good summary of what you're doing now. Speaker 4: (16:37) Yeah, absolutely. I think the underlying theme there, and actually before I get into the underlying theme it's just funny, a story came to mind, Lisa, the other day I was talking to a friend and the friend said, you know, the best psychologists all have some sort of underlying psychological issue that they've worked on. And that's why they became psychologists, right? I never intended to be in this world at all. I was going, like I said, I was going to build an app because everybody built apps, right? And I got into this world because I had to fix myself. And as I was fixing myself, I did it in something that made sense to me, which was data. So very strict measurement, very much defining objective strategies and tactics and executing with a certain level of discipline. Cause like we talked about earlier, you and I take things to extreme, right? So you know, just taking it to a certain level of extreme with the discipline side of things. So I see things a lot better. Speaker 3: (17:37) Yeah. Amazing. So you've now actually made a new empower, if you like, around helping people with high-performance, helping people with their health issues using the lightest. And this is what I find fascinating and we're, I think the future is turning to the old model of you had to go to medical school to become a doctor, to become an expert in health. And that was pretty much it. You were a nurse, a doctor or a you ma. Maybe there was a chiropractor or a naturopath in your town or something like that, but they were, you know, re era. And there was this, this linear thing thinking to the medical model and that is dying. Thank God is changing. We made the allopathic medicine model, but we also need it to change and we need the what would you call them? Accelerate viewpoints because, and you don't necessarily have to have gone to medical school and to have some really amazing insights. Speaker 3: (18:43) I mean you just mentioned Dave Asprey, the who, you know, some of the things I agree with and some of them I don't, but like he has certainly blazed the path for someone who's not himself, a medical doctor who's also come from, can walk computer science and his case into the, to the world of health and applied that, that brain and that, that ability and so a new area and you see this happening again and again. So what are you passionate about now? So you have the podcast decoding, superhuman, you have some incredible guests on there. What is it all about for you now? Speaker 4: (19:22) Sure. I guess before I outline what I'm involved in, what I'm doing, let's construct the theme to have it all makes sense, right? If you look at my personal mission, at least to what it's become over the past couple of years, it's to elevate the human experience through health. Now what do I mean by that? Elevating the human experience making, are enjoying our personal lives, enjoying our work lives, operating a certain level of energy, being compassionate being in, in shape, in the sense that, you know, extending health span, all of that is elevating the human experience. And the best way I know how to do that is through health. And so when I say that, that's the, the underlying theme of everything that I do. Now, you just mentioned one thing that I do, which is the podcast and the decoding super even podcast is top 100 business and careers podcast on iTunes and several different countries occasionally the U S as well, but also it let's go kind of from left to right. Speaker 4: (20:34) I do have the one to one consulting business where I work with predominantly entrepreneurs and executives through a process called health optimization. I'll come back to that in a moment. I work with an organization called health optimization medicine and practice. And that's a nonprofit foundation founded by my mentor, Dr Ted Achacoso's, which is basically U S and now I'm opening up the European arm here and there'll be an Australia, there'll be an an that arm as well. And it's kind of going global now in 2020 and then I, I do have some involvements and a, a nootropic which is going to be launched later this month. And I can talk about that too. So there's, there's a lot going on and there's more projects in the waiting, but you know, people look at me and say like, Hey, are you doing too much? Well, I view it all as complimentary. Speaker 4: (21:28) I'm just sort of solving my problems along the journey. Right? And so if I look at the one-to-one business, I only work with executives and entrepreneur types whether that be in digital marketing or whatever industry it is, because I know that lifestyle and I came from that lifestyle. And so I can speak a lot to that lifestyle. There's certain lifestyles that I just can't speak to, I can't work with, but we apply a rigorous amount of data. And perhaps Lisa says, okay, if I go down the health optimization realm right now cause I'm interested in more than anything and this wraps. Sure. So let's, let's talk about health optimization. And so as I mentioned this is all something that I'm spreading the word on through an organization called health optimization medicine and practice homehope.org. And so and so that organization is designed to teach doctors and health practitioners on how to optimize for health. Speaker 4: (22:29) If we think about why we go to a doctor currently, and I have nothing against doctors, right? I have zero qualms with the medical industry at all. It's people go to the doctor because they're sick because they want to get better from some disease. They want to discover what diseases, et cetera. But who are you going to for your maintenance? Right? Who are you going to for the tuneup if you're that car, we don't have anybody that just does the oil change and sends you on your way. Well, health optimization, medicine and practice is that oil change. And so what do I do now with my entrepreneurs? My executives is, look, I, I still have and gather a lot of data. I'm very comfortable with data, but I also think because we now have the ability to test for a number of different things, it's the best way out there because not only can we just assign probability, which is what we can do with genetics, we can actually see where your cells are right now. Speaker 4: (23:31) And that's through the metabolome. So when we start working with a client, what we're doing is we're measuring the levels of metabolites. We're looking at things like nutrients and hormones, we're comparing those to optimal ranges. And I'll define what optimal ranges is in a second. And then we're balancing really through the idea of a network. So rather than just taking one esoteric biomarker and focusing on it, I'm looking to upgrade an entire network. Because if you take one esoteric biomarker, all you're going to do is just Jack the thing out of balance again. And so what we want to do, you don't kind of ad hoc overhauling network, you balance networks. And so what we're actually doing is we're measuring those metabolite levels and looking at nutrients and hormones and then we're balancing that by looking at really what your optimal formo levels as well as nutrient levels should be through a 21 to 30 year old. Speaker 4: (24:30) Now I'm not a doctor so I can't prescribe hormones and so what do I do is I focus on the nutrient side of things. There are certain things I can do on the hormone side and there's oftentimes where I pair up with physicians and do focus on optimizing in that way, but that is where we're looking at is how do we upgrade your network so that your nutrients are balanced and so that you're able to perform at your absolute best. Now there's no claims there. I'm not saying that this anything here is treating disease. We're not doing that. All we're doing is giving your body maintenance and that allows you to perform at your best for longer and with a longer degree of health span Speaker 3: (25:11) In longevity, and this is absolutely Misa below mix. This is a new term that since listening to your podcast and coming across dr [inaudible] in, in starting to delve into his world, which is sine amazing. And this is providing a new lens to look through and looking. So this is even an hour practice with our company. We do epigenetic testing and if we, we have certain limitations, we can't go outside of our scope of practice and we have to bring in sometimes physicians and other experience in areas and that can be quite difficult. Certainly lock in more streamlined way of doing that and could be the people to work with. A little bit limited here where we are. But this is a, another lens to look through and I'm, I'm really wanting to layer on, you know, you have the expertise in like you've done with the genetics tasting and things like aura ring and using different data points and now your board and dr Ted's whole way of looking at it. Speaker 3: (26:26) And I, I, I have to talk to you privately afterwards about what it to, to become involved with that because I'm quite excited. I'm hoping I'd have the intellect to do it, to be honest on listening. Like, Oh my gosh, that guy is intelligent. He's a, he's a ball. He's statistically one of the smartest people in the world. So yeah, the Turlock, he is literally one of the top people in the planet. So that's what I'm saying. Everyone can keep up with it. But so what are the, you're working mostly in these cases still on the one on one system or are you sort of doing this for, can people contact you to get help or how does they work? Speaker 4: (27:10) I generally work with the, and the website hasn't been updated in a while and it will hopefully be up to it very soon. But I generally work one-to-one with people and it's almost strictly referral. But on occasion I do take in new clients. And so what we do is we do measure that metabolome and that. So let's just define those terms. Right? And so if you think about genetics, genetics is really popular, really sexy right now as is that the genetics and genetics is really the blueprint of where you should be, right? If you think about putting together a building, a, it's the blueprint of where you should be. It's that architect has drawn something fancy up. And I had the pleasure of doing one of these presentations to a group here in Amsterdam and there's actually a construction person in the audience. And I asked him, how many times does the blueprint actually end up as the actual house? Speaker 4: (28:02) And much to my amazement, I thought it would be somewhere in the range of like 10 to 30%. So zero. And you think about that, what actually influences the building? It was environmental factors. It was the soil, it was material. They'll ability. Now if you passport that over into our lives. Environmental factors are certainly something that we face every day. Material availability in terms of the nutrients that we need the weather outside, whether or not you gain enough sun and that's really your epigenome, right? And so we can keep going further and further down. The Omix line is, Oh, mix is very trendy right now too. And we can eventually get to this thing called the metabolome. And so the metabolome is really looking at yourselves and seeing what is happening right now and what has happened. And so what do I mean by that? Speaker 4: (28:57) We look at metabolites again across nutrients and hormones and we can determine things like vitamin deficiencies but also looking at anything from neuro-transmitters, although that's a little bit less reliable to heavy metal toxicities. And so, and then once we have all that information, what we can do is very much quite clot, a precise roadmap. And each one of my clients gets with is basically like a 10 to 15 page, a nutrient and lifestyle plan. And what they do is we're able to come very close and become very precise as to what nutrients you need to balance that network. Because after all, we're coming back to balancing the network. I can give another analogy if you want. Sure. So if you think about humans as as a whole, we're actually a collection of organisms. And what is interesting about the term super organism is the term superorganism really just means your collection of the same organism. Speaker 4: (30:03) The actual term that I prefer to use and was taught to me of course by dr Ted and Dr. Scott, who I know you had on the podcast before, is called Hola biomes. And the whole of Vajente is really just acknowledging that humans are actually a collection of organisms and we can measure those organisms through things like metabolomics and the health of those organisms and allow that to be a balancing mechanism. And so let's just run some examples here, right? And if you look at our current cell, our current cell is constructed of a symbiotic relationship between mitochondria and a, an ancient cell, right? And so that symbiotic relationship came together. And so we are actually fundamentally a collection of organisms. Now add on top of that, you have things like microbes, you have gut bacteria, you have viruses, you have all of these things, and you have this external environmental influence. Speaker 4: (31:02) And there's this book in 1992 and I'll get you a link in 1981 or Nigeria to that came out that turned this, the whole of biome. And so you as a human are actually a whole lot beyond. And so we can assess this whole of ion to actually measure. And again, I am very much into data measure the health of you and sir use it as like a term of benchmarking, right? So you come in every, I like my clients to see me, you know, once every three to six months for testing. And then eventually we want to get them to once a year, but usually starts at once every three to six months. And then when they come in, we benchmark how your whole Obiang is doing, you know, how are, how's your gut bacteria? Do we have good bacteria balances there? Do you have any sign of parasites there? Are there any sort of factors that we need to look at on the nutrient side? And once we benchmarked it, we then start to optimize, right? And so it's what I find, I consider it to be the most elegant equation to human optimization author. Speaker 3: (32:09) Wow. So this is the nix label from just what you've been doing along with the genetic testing and coming out with data that, that producers and actually looking at. So how is the hollow buoyant and the metabolome actually tasted? Is it through blood? Is it through a combination of, you know, saliva, blood, urine, you know, how was it actually the data collected? Speaker 4: (32:35) Well, that's a very good question. And so fundamentally with any clients, I run three tests now. Those three tests are a blood draw, a urine sample, and a stool test. And those three are allow us to assess metabolites as well as bacteria in balances. And so we're able to gather the picture in a very simple manner. Speaker 3: (32:58) Wow. And then [inaudible] and this is now international, the home hardcore Donald. So you don't need specialist labs to chase that. Can you use your name? Speaker 4: (33:09) Yeah. You can't get in exactly. Walk down to your local doctor and say like, Hey doc, I want to test. You know, I want my I w yeah, first off, you know, you may get some pretty weird looks if you mentioned the word hold by aunt, but it's pretty hard to go down and say like, Hey, I want to go test eight. Oh, HDG. Right. Which is oxidative stress or DNA damage. Even that's pretty difficult to test at most local labs. What we, what we do is we use a specialist's lab around their global little bit less of a presence. They have a presence in Australia called Genova diagnostics. They're based in Asheville, North Carolina, which is where my parents live. So I get to go make the pilgrimage every so often down to their labs. But yeah, Genova diagnostics provides those tests. You can get a metabolome analysis from other labs. And of course we're looking at those labs. But this one we use current. Speaker 3: (34:08) Wow, that's amazing. Okay. So they knew you'd get these tests done and then you can, you can analyze them for these things and give them specific recommendations, both lifestyle nutrients in other interventions, I imagine. Absolutely. And this is, so this is all, you know, like we both agree that, you know, the ambulance at the bottom of the cliff approach is not where we want to be. In for our own health and for the health of our loved ones and the people that we work with. We want to be the, at the top of the class before the stuff happens. And this is the key difference in the approaches. And then a second difference is that our allopathic models are very pharmacological based. And you know, don't you believe that that money doesn't talk, you know, the money that pharma companies have at talks and, and that is influencing the decisions fate that your doctors are making. Speaker 3: (35:09) And it's also the way it's set up. And so this has been a very one sided, you know, and, and farmer pharmical logical intervention certainly has the place, but they have a way to bigger space in the world, I think at the moment and comparison. And I think , you know, like looking at hyperbaric and Dr. Scott shows, who's now involved with you guys is a, is a classic example of a therapy that works that doesn't have a pharmaceutical backing or no way to make tests because there's no way to make money out of it. They can't patient account, patient oxygen cause it's already there. You know, you've got situations, same with hormones, you know, by bioidentical hormones. You know, they haven't been able to paint it them. So they made some physical Mons for women and hormone replacement therapy and, and you know, that caused a whole lot of headache. So there's this, this is systematic problems in a boom boom, top of a, of a generations within the system. And a lot of it is, is very much a stick a bandaid on the, on the wound and not look at, well, where did the wound come from and why is it there and what's causing it, you know. And that's what we have more about and learning. Speaker 4: (36:23) Yeah. And, and I think, you know, even taking it one step further, because you know, looking at the wound and seeing where it comes from, that's a lot of what functional medicine is doing and they're doing well. What a health optimization does and health optimization, really medicine and practice is what we're doing is as you know, functional medicine, we'll look at that quote unquote root cause and what health optimization medicine practices doing it is seeking to just balance and perform that maintenance so that, you know, going down the line rather than having to basically take all of the life's maintenance and put it, you know, I, I come from finance, so like let's feature value all of life's maintenance into this one big event down the line, which in my case probably would have been a heart attack. Why don't we do little bits of maintenance over time so that health span happens. Speaker 4: (37:25) Right? And so I think going back to the finance analogy, it's like an annuity every year or every six months or even three months. You come in, you get your Tufts, you benchmark, you figure out where you are, and then you seek to optimize and balance or balancing networks here. And what we find is, is that people tend to perform very, very well, and you can start to measure these things, right? There's a, there's really cool clocks out there. I'm a big fan of the Horvath clock. I just enjoy it. And I know that these clocks are evolving every single minute. You know, people like chronometer my DNA age, a few others that are looking at methylation marks on the Nissan and the on DNA and determining biological age. There's also something out there called the grim age, which I'm super excited about because that one is, Speaker 3: (38:13) Oh, that's a new one on me. What's interesting, right? And this is Speaker 4: (38:17) Not for everybody, I'll admit this, but for people that are somewhat sadistic like me, this is apparently an a way to extrapolate a distance between now and first potentially more tality event, right? And so it's like now in between now and the time you die, but you can do stuff about it, right? And so I'm the type of person that if I have an issue, I want to be confronted with it. And so that, you know, I wasn't the kid who basically when I found out I had heart disease, I broke out a spreadsheet and figured out, okay, what's the average is a person dies and I put that day's number in my spreadsheet and that motivates me to, that motivates me to do stuff every day. Now that's not for everybody, right? And I recognize that I'm a little weird in that sense, but these are types of things that are out there that allow us to get not only not only just more, more data points, but also allows us to benchmark the success of our modifications, right? Because all we're doing is nutrients and lifestyle modifications, but nutrient, lifestyle modifications can be very, very powerful. Speaker 3: (39:35) Underestimated it, you know, like the basics and sometimes underestimated. We get into all this fancy stuff, but sometimes it comes down to are you drinking, are you sleeping? Are you getting sunlight? Right? Like, are you connected to nature? Are they saying those clocks? Or I'll have to get the links to that because I'm very sort of beach marking, biological age or, and, and you know, they, my age one, it sounds very interesting because that's something that's missing in our regime right now is being able to, is actually getting that macro for people and benchmarking and all these things cost. So it's always a cost way up. But it gives you something to aim for when you've got a line drawn in the scenes. I think Speaker 4: (40:17) I think absolutely. And I think a grim age is not yet commercially available. So the biological age is there are two companies that I know of that are producing them at various price points. The other thing that is really interesting and it's something that, yeah, the other one that I like for benchmarking is the promise 10 global. There's promise tents for everything, but it's just a simple survey and the statistics behind it are quite promising. So that's something, it's cost-free, but it's a great way to benchmark clients and their success rates. Speaker 3: (40:55) Okay. Okay. I'll, I'll be definitely get paid to get those links off here because a, a beach mapping system is what's missing and now, yeah, right. Speaker 4: (41:03) And what we, what we do, and it, sorry, I know I cut you off, is I gather a lot of data, right? It's like hell, I've said the word data. How many times? Speaker 3: (41:12) Yeah, you're right. Speaker 4: (41:15) So anybody that works with me has to be on board with that. And so whether that's from your wearable, whether that's from whatever survey that we send you anywhere from every day to every week you're, we're gathering data on you to make sure that everything that we're doing is working. Cause after all, like humans are complex adaptive systems to say we're not, is just categorically wrong. Right? And so when we look at a human as a complex adaptive system, we need to build in feedback loops. And so how do I get a person to, to sleep more than four hours a night? Well, I can't tell them to get eight hours a night just because the book says, right. What is actually physically happening there is, okay, let me show you your aura score every day. And you know, or whatever. It doesn't have to be aura. Let me show you that score every day. And that when that score goes up, how you feel and if you feel better than you subjectively just want to get more sleep. And so what we're doing is using the technology and leveraging the powers of technology and data to help assist in those behavior modifications. Speaker 3: (42:20) Brilliant. Because people need to have and some people to move that data-driven than others. Some you recommendations. And that's, you know, working with your epigenetic type if you'd like, as to how much science you need behind the information. I like you. I like to know the why and the Watson dig 10 layers deep down, stand up. Other people, maybe not so much, but having these beach max does give you a line in the, and it's like having, it's like if I say to you by my, you know, we're going to try a new up for a hundred K, you've suddenly got a line in the same and you've got a timeline and you've got a goal that you're going towards and therefore your teen Tom's likely more likely to get the us than if we don't benchmark that. And if we don't have that goal in place to help them in knowing where you started from and where you finished and then you can actually see, I came all that way and that's a really powerful thing I'd been on. Speaker 3: (43:13) I'm really aware of, of the time you've, you've been super, super generous with your time today. And I am super excited to find out more. I think that dr Ted stuff is definitely on my horizon once I've gotten through some other qualifications that I'm doing at the moment. They might be the next one. Yeah, that would be, it'd be super awesome. And I'd love to stay super connected to you and what you're doing because I love, I love just being around people that have the, the, the knowledge that you have, the breadth of experience that you have and the dips that you go. You fascinating. Your, your show is amazing. So everybody must go and subscribe not only to this podcast, obviously pushing the limits but to, to decoding superhuman, decoding, superhuman. And in there any last words that you'd like to share, boomer to people out there what's your most important mission in life and what is, you know, a thing that's really important for you to get across and people like that you would, Speaker 4: (44:17) Yeah, sure. So let, let's start with that mission. So I mentioned it a couple of times, but it is elevating the human experience through health. And I look at the world and look, I don't need to go back and go into any sort of politics or anything like that. If I look at the world and just kind of the problems that we face or the Speaker 5: (44:49) Okay, Speaker 4: (44:49) You know, where we need to go in order to, I get in a lot of discussions about the future of work, right? Just because that's what I get hired as a keynote speaker to do a lot. Let's talk about the future of work. And so when I look at the world and sort of elevating the human experience through health, there's a lot we can still do as humans before we all of a sudden get taken over by Skynet and go into this matrix type scenario. Right? And so I think people, you know, in terms of the mission, elevating the human experience through health in terms of the point I want to get across to people, start measuring if you are, no matter where you are, you don't have to be super human. You don't have to be, you can be like on the other end of the continuum, right? Speaker 4: (45:39) And just start measuring where you are. Start associating behaviors with a certain type of measure and get out a spreadsheet, get out a piece of paper, whatever it is. Assuming you're listening to this podcast, I assume you have some sort of modicum of technology you know, getting out a spreadsheet and start tracking this stuff and just started associating what you're doing with a feeling. And that's just a great way to start tracking. You can eventually get into all this really cool high level tracking that I've been talking about today, but really start measuring. That's something that will help you achieve your goals faster. And will really just make the whole journey a lot more, lot more fun. Speaker 3: (46:22) Yeah, a lot more fun and move a lot more little goals to aim for when you know what you're dealing with. And this is something, you know, that doesn't have any come naturally to me, but I'm definitely moving more and more in that way. We met, you've been super, super generous with your time. I really appreciate the work that you're doing in the world. I'm excited to see where it takes you and however we meet working with you more. So people can go to decoding superhuman.com which be your website and you can around, they can reach out to them. Speaker 4: (46:53) Sure. so www.decodingsuperhuman.com is the website. That's where you can find all the podcast episodes again, iTunes, Spotify, SoundCloud, every podcast destination there is. We released six episodes a month. And I will also, you know, you can find me on Facebook, Instagram, LinkedIn. I've basically gone through my new year's rerock of how I want to address social media. So you'll see me more in posting there as well. So I look in and please say hi like I am, I respond to every message is everybody knows so please say hi and let me know what you think of the opposite. Speaker 3: (47:32) Definitely reach out, check out the podcast, absolutely Speaker 2: (47:36) As a, as a master's, a minimum and ask the questions cause that's where conversations start and where you learn. So thank you very much, much. I really appreciate your time today. Speaker 3: (47:46) Awesome. Thank you so much. And one more plug. I guess if you want to check out the stuff that we talked about, Speaker 4: (47:51) About on the home hope side of things, just go to home hope.org yup. Speaker 3: (47:56) Yeah. Home hope.org. It's the website or Speaker 4: (48:00) We're working on launching the education foundation. It's part of, it's already launched. But it's something that you guys can check out and let let us know what you think. Can you can just drop me a message on social media? Speaker 2: (48:10) Yeah, it's definitely on my horizon. I want to, I want to get there. So thanks for doing that and thanks for spreading that word cause it's a completely new lens to look through. Thank you very much glioma and we'll talk again. Speaker 3: (48:21) No doubt. Absolutely. Thank you. Lisa. Speaker 2: (48:24) If your brain is not functioning at its best in, check out what the www.vielight.com do now. Be like producers, photo biomodulation devices. Your brain function depends largely on the health of the energy sources of the brain cells. In other words, the mitochondria and research has shown that stimulating your brain with near infrared light. Revitalizes mitochondria. And I use these devices daily for both my own optimal brain function and also for other age related to client issues and also for my mom's brain rehabilitation after her aneurism and stroke. So kick out what the team www.vielight.com that's V I E L I G H T.com and use the code T A M A T I at checkout to get 10% of any of the devices. Speaker 1: (49:15) That's it this week for pushing the limits. Be sure to write, review, and share with your friends and head over and visit Lisa and her team at lisatamati.com.      

Episode 36 of Nighty Night Season 2. Another back 2 back session with my friend Omix. Liquid and deep drum and bass. Enjoy!

Episode 35 of Nighty Night Season 2. A B2B mix between me and good friend Omix. Deep vibes ahead.

Bringing it home - Become The Hero of the Bedroom   Transcript: [00:00] Welcome to another episode of the recharge podcast. This is segment nine of the bedroom hero behind the bedroom door and I just want to kind of wrap things up here in a summary fashion and just share some information with you. So I want to start with a quote that I heard from a a entrepreneur, a billionaire, and it basically discussed excuses, excuses, mindset used by those who are focused on themselves and their inability to solve the problem. It has nothing to do with reality and doesn't approve anything and I think that's applicable for a variety of reasons. In the context of what we're talking about in this series of bedroom hero and that a one size solution isn't for everybody. I see a lot of men that are frustrated that they've tried things before it hasn't worked and it's they're told that it's impossible, that their problem is not solvable. [00:50] That they're just going to have to deal with this and learn to cope with it. And I think that really sort of A. I'm trying to figure out a way to say this nicely, but it doesn't do a service to the person they're suffering with an issue they want to solve a problem and not looking beyond or exploring things that maybe are novel or on the cusp or cutting edge or fringe. Just find a solution. Uh, there are plenty of people out there that are doing amazing things and pushing science forward. So just keep looking. So in this past few segments here, we talked about, uh, you know, the issues behind the bedroom door, the statistics on how sexual dysfunction affects not only men, but also women to equal, if not greater, percent. Also shared a exercise, tips on high intensity interval sprinting and lifting weights in terms of testosterone. [01:39] And the subsequent section talked a little bit about some nutritional things that are cofactors for hormone production and particularly for the purposes of this men's health focused segment, testosterone production. A shared a little bit about some of the herbs and some of the things that are a little bit more fringe from anecdotal and some science behind it as well. Obviously, do your own diligence. This is an educational podcast. I'm not telling anybody listening to this to take a particular substance, something that needs to be coordinated and measured and discussed with somebody who knows your unique physiology, medical history and medications. Next moved on to some biohacking things involving red light and cryotherapy. Fascinating, fascinating science. If you're not familiar with Wim Hof, the iceman, just google him. He's got several world records and what he's been able to demonstrate with cold therapy and physiology is truly mind boggling. [02:32] I also shared some data on sound wave therapy, whether it's for erectile dysfunction or Peroni's disease and how that works and can really improve and change a life for a number of people, and then I combine that with some prp and stem cell discussion and some novel therapeutics that are being used to treat more refractory cases of ed or to deal with people who now don't necessarily want to take a pill. I think the tendency in in the US at least is to prescribe a pill and if that doesn't work or if it's a side effect and you prescribe another pill to take care of the side effect of the first one and on it goes and it's not really a viable solution. The concept of precision medicine or Omix is this. You are n of one and if you look at a standard bell curve distribution, people lie on the ends of either spectrum in those are actually cutoff, avoided, ignored, however you want to view it in the mean. [03:33] The middle point is what's focused on and so a lot of people fall outside of the boundaries and so what is often deemed as a standard therapy or quote normal doesn't take in account a whole host of people that are either below or above for a variety of reasons. Whether that's genetics, hormones, lifestyle, and to try to use the common standard approach for those people. Oftentimes is met with disappointment or worst case scenario disaster, but most often frustration. And so really having a precision approach to each person. Their unique problem. Whether it involves some genetic testing, obviously hormonal testing is vital for what the point of this segment and these previous eight sessions were about in. So it's really finding somebody who wants to partner with you to find a precise answer for your unique situation. So I hope you found this helpful. As always, let me know if you have any questions and please, please no more gas station, Madison no more horny goat weed or I can't even think of the names of all the things that I've seen in the last week because I've been specifically looking at them and chuckling at them and a feeling a little bit remiss that people are actually spending and wasting their money on these things. [04:41] So as always, have a fantastic week. Be Safe, be well, and I'll talk to you soon.

Episode 23 of Nighty Night Season 2. This one's a B2B2B with Dissent (former Hellx) and Omix.

Episode 17 of Nighty Night Season 2. This one is a B2B session with my good friend, Omix.

Henk Van Dongen is the Director of Marketing at Omix-ADA. Omix-ADA is the world’s largest independent manufacturer of Jeep parts and accessories. Over the years Omix-ADA has expanded the business by adding and building brands like Rugged Ridge, Alloy USA, Precision Gear, and Outland Automotive. By continuously investing in new products and product lines, Omix-ADA is able to service the Jeep enthusiast market covering from 1941 to the most recent models. However not only do Omix-ADA specalize in Jeep parts and accessories but they also have an exclusive collection of cars from 1941 with a view to preserving the Jeep heritage. Make sure to follow us and subscribe!NoBraking can be found on Instagram and Facebook

Angello Omix presents InHouse Cast the second episode of the house music podcasts, a nice mixture of deep & tech house, one hour of pure electronic music. for playlist contact : contact@heavy-records.com ----------------------------------------------- www.soundcloud.com/angelloomix www.youtube.com/angelloomix www.facebook.com/omaryangelloomix Mail : contact@heavy-records.com

Angello Omix presents InHouse Cast the first episode of the house music podcasts, a nice mixture of deep & tech house, one hour of pure electronic music. Tracklist: - &ME - After Dark (Original Mix) - Format B - Chunky (Original Mix) - Simone Vitullo, Cari Golden - Cracks feat. Cari Golden (Original Mix) - Plastikman - EXpand (Tale of Us Remix) - Martin Eyerer, Markus Homm - East Coast / West Coast - Andre Hommen - Battery Park - Jay Lumen - Our Freedom (Original Mix) - Sonny Fodera - It's Like That (Original Mix) - Purple Disco Machine - Where We Belong (Original Mix) - Gregory Porter - Liquid Spirit (Claptone Remix) ----------------------------------------------- www.soundcloud.com/angelloomix www.youtube.com/angelloomix www.facebook.com/omaryangelloomix Mail : contact@heavy-records.com

Janet Jansson is the Senior Staff Scientist in the Earth Sciences Division at Lawrence Berkeley National Lab. Her expertise is in molecular microbial ecology and “omics” approaches with a focus on soil, marine sediment and human gut environments.TranscriptSpeaker 1: Spectrum's next. Speaker 2: Okay. Speaker 1: Welcome to spectrum the science and technology show on k a l x Berkeley, [00:00:30] a biweekly 30 minute program, bringing you interviews featuring bay area scientists and technologists as well as a calendar of local events and news. Speaker 3: Good afternoon. I'm your host, Brad Swift. Today's interview is with Janet Jansen, UC Berkeley, adjunct professor of molecular microbial ecology. She is a senior staff scientist in the Earth Sciences Division at Lawrence Berkeley National Lab and president elect of the International Society of microbial [00:01:00] ecology. Her expertise is in the area of molecular microbial ecology and Omix approaches with a focus on soil, marine sediment and human gut environments. Today she talks about the human microbiome project, the Earth microbiome project and American Gut, a crowdsourced research project. Onto that interview. Janet Jansen, welcome to spectrum. Hi, what'd you give us a short description [00:01:30] of microbial ecology and give some examples of complex microbial communities. Speaker 4: Sure. So microbial ecology is the study of micro organisms in the environment and their interactions with other microorganisms, plants, animals, that particular habitat that they happen to be living in. So it's really not just studying a single microorganism, but a community of microorganisms. Uh, so some examples [00:02:00] of complex communities. Well, the most complex ecosystem is soil and that's because it has such a diversity of microorganisms and it's really packed full of microbes. So there's so many microorganisms living in soil. So that combined with the diversity makes it a very complex system. The human ecosystem is very complex. Our own intestines have a very complex microbial community. [00:02:30] The oceans or other examples, sediments. So I think this is my community college that you had to think differently than one would when you study organisms in pure culture and their physiology is much more complex Speaker 3: and microbial research seems to have jumped in stature in the past few years. You have a broader view of it than I do. What's your take on the trajectory of microbial research? I think Speaker 4: [00:03:00] particularly the microbial ecology part has increased in stature recently. Microbiology as a field has been around for a long time. But the thing that I think has really boosted the field of microbial ecology is the advent of these new technologies, the new tools to be able to really look at these complex communities and understand them. Until I guess it was about the 1980s there wasn't [00:03:30] any way to really look at these micro organisms in soil. Again, I'll use that as an example, unless you cultivated them onto augur media or looked at them in a microscope. So when the field was limited to looking at what was possible to cultivate, that was only a fraction of the microorganisms that live in soil habitat. So probably fewer than 10% could be cultivated. So the majority of the organisms that were there, [00:04:00] nobody knew anything about them. Their identities or their functions were really unknown. Speaker 4: So it was considered like a black box eco system. But after the late, I guess the 80s and into the 90s there were the developments in DNA extraction techniques. So it was possible to extract DNA from soil and then came PCR amplification methods and methods to be able to amplify specific [00:04:30] pieces of DNA that you had extracted that made it possible to actually study soil microorganisms without cultivating them. And now we have these deep sequencing technologies, so it's really made it much easier to do very deep analysis of these communities and not have to rely on cultivation. Speaker 3: The human microbiome project is in its last year. What were the goals of it and can you speak to that about what the goals were and what you think [00:05:00] you've found out? Speaker 4: The first stage of the h and p was to sequence different bodies sites and understand which micro organisms are residing in different sites in the human body. And so this was looking at a large cohort of humans, healthy humans, and just basically understanding who are the microbial inhabitants of the human body. So that part is winding down. We have that knowledge now. We know that there are different micro organisms that live on your skin, [00:05:30] then in in your gut for examples and also in the oral cavity. So these organisms are specialized to live in different parts of the human body and there are differences between different individuals though. So that means that each human has their own individual microbiome and it can almost be used as a fingerprint. So that was a successfully completed project. The next stage there has been a recent call too, I think it's even called h and p two [00:06:00] to go the next step. So to use other kinds of methods to look at not only which microorganisms are there, but what are they doing. So this would be looking at the functional capabilities of the human microbiome. Another thing that is still ongoing with the h and p is looking at how does disease influence the human microbiome and vice versa. What is the correlation with the microorganisms living with us and disease? And it seems like there are many different links between many [00:06:30] human disease that send the human microbiome Speaker 3: [inaudible] [inaudible]. Speaker 5: Our guest today is microbiologists, Janet Jansen. In the next segment she talks about the microbiome and disease correlation. This is k a l x, Berkeley. Speaker 3: Well, and often in science there's a lot of correlation [00:07:00] that goes on and sometimes you get fooled by the correlation. Sometimes you don't. Are there strategies you use in terms of validating what you think correlates? Speaker 4: Oh, correlations are can be quite challenging. Definitely. So, um, that's an interesting question because then one of the things that is very tricky is if you find a difference in an environmental sample, for example, with the civic treatment or in a human with disease often all we have, [00:07:30] we can then say, well it's correlated to this organism that is higher in abundance or it's correlated to this protein that is higher or lower in abundance. That's a little frustrating. So that the next step, and we're not quite there yet in this field, would be then to say, okay, go beyond correlations and then actually do the proof, you know, to take that organism like Cox postulates, you then prove that this correlation that you see is actually [00:08:00] occurring. But it's difficult with these complex samples, like I was saying before, because you have to move away from the complex environment where you have all these different factors. Speaker 3: So the complexity defeats you in a way because you can't isolate the specific from the general. Exactly. Exactly. And so within this correlation of disease, are there particular diseases that seem to be top priorities in a sense or are most likely to be effected by [00:08:30] the microbiome? An example of Crohn's diseases, Speaker 4: Crohn's disease is the example. I would give us a very clear example and also other inflammatory bowel diseases where there has already been established a link between the gut microbiome and the disease. The details are still under investigation, but there is a difference in the micro organisms that inhabit the intestine in individuals that have Crohn's disease compared to healthy. [00:09:00] So that's known. Speaker 3: And is that the case with ulcers as well? Or they were sort of one of the first, it seems that had this association with the microbiome in the gut, Speaker 4: right. So systemic ulcers, there was a Nobel prize awarded for the discovery of [inaudible] go back to Pylori as the cause of ulcers in the stomach. And so that's a good example, this specific microorganism that can contribute to a disease. And then of course a lot of medications were subsequently [00:09:30] developed to dampen hillcoat back to pylori through new research. We know that there is a considerable diversity of microorganisms in the stomach that people weren't aware of before using these techniques and also in your teeth and then in the oral cavity. There's a very large diversity. I should mention that one of the things that is a really hot topic right now is the link between the brain and the human microbiome, including [00:10:00] the gut microbiome because it's known that some of the metabolites that are produced by these intestinal microbes can pass the blood barrier and then migrated essentially in impact the brain, so some current research is looking at the link between autism and schizophrenia, these kinds of things. Then I think that's really interesting. That's one future direction of the field. Speaker 3: The new initiative in brain mapping exactly [00:10:30] now ties that together. That would be great. At least the findings here was just a new funding. Speaker 4: Yeah, I know. I don't know if they've really decided to make that link for funding, but it probably will come. Speaker 3: Can you talk a bit about American gut and how it's set up to help people figure out their own microbiome? Speaker 4: Sure. So the American get is, it's a relatively new way of doing research [00:11:00] is crowdsourcing. And the idea is that if a person such as myself is interested in knowing quip, my gut microbiome is I can pay a small amount, it's like $100 to get my sample sequence. So that is the way that the project is funded. And so this project, it had a funding goal, I think it was $300,000 to be able to launch the sequencing. And so there was the campaign [00:11:30] and it was sent out to the community and through connections such as Facebook and another with this nice little carrot that if you pay $100 you can get your microbiome. And in addition to gut, it could be your skin sample, oral cavity, your pet. And so this idea really caught on and is a good example of crowdsourcing for funding. Speaker 3: And how are people able to leverage that information? [00:12:00] Is there some characterization that you do as well? Speaker 4: The data that they get back is, it's different kinds of information. So first which micro organisms do I have? That's kind of fun to know. It's sort of like 23 and me where you get information back about which genes you have in, which kind of markers for different things. So depending on your microbial community composition, you may have markers that are more indicative of health, certain kinds of diets like [00:12:30] vegetarian or a protein rich diet, even obesity, there's certain microbial indicators of obesity. So that's just interesting. Another thing that is valuable for the consumer, the person who does this is that you can compare your microbiome to everybody else's. It's all anonymous of course. And nobody knows who's this, who's, but you have your own data and can see how your microbiome fits into a pattern. So do you cluster [00:13:00] with obese people or with a disease type microbiome or a certain kind of eating pattern Speaker 3: and are these online tools that you have available through American gut for people to do this kind of characterization? Speaker 4: So the analysis has to be done by the actual scientists that are doing the samples because it's still quite elaborate and involves a lot of bioinformatics. So currently it's not possible [00:13:30] to do a lot of that on your own, but still to get an output, the actual data, the results of the analysis is what the individual can get through this project. Speaker 2: [inaudible] you were listening to spectrum on a k a l x Berkeley. Our guest today is Janet Jensen. In the next segment she talks about the earth microbiome project. Speaker 3: [00:14:00] Can you talk a bit about the earth microbiome project and maybe differentiate it from the human project? Speaker 4: Yeah, sure. So the Earth microbiome project, which I'll call the emp, is, um, instead of just looking at humans, it's including basically all of earth. So it has a very lofty goal of understanding earth microbial diversity. That project also relies [00:14:30] on collaborators, so it's sort of a crowdsourcing project as well, but limited to the scientific community. So the way that Earth microbiome project works is if a collaborator has an interesting set of samples, for example, from the deep sea or from Yellowstone hot springs that have the required kinds of environmental data, so Ph, nutrients, things like that. Then they can [00:15:00] send an email to the steering committee and say, well, would this study be of interest to the earth microbiome project to the ENP? And then the steering committee looks through the data and decides whether the environmental data is sufficient and if the samples are filling a hole and providing novel information and if so the samples are accepted and the sequencing is done without any costs to the investigator. That's the win win scenario for the emp [00:15:30] because the investigator does of course provide the funding for the study and collection of the samples and the emp provides the funding for the sequencing. Now the funding for emp is also kind of fuzzy because it's through different kinds of companies that have supported by providing regions or equipment and then in turn they get advertisement through the emp that they're sponsors of the project. And so that [00:16:00] also seems to be quite successful. Speaker 3: And the intent again to build a catalog Speaker 4: basically, yes, to build a catalog to find out who's there and are there patterns. The nice thing about heading samples from so many different disparate environments is that you can see, well does this particular microorganism occur across different kinds of environments or is it really endemic only to one kind of habitat? And if you tweak the environment, [00:16:30] for example, with climate change to have increases or losses of certain members of the community that are predictive, one of the aims is to have something like a Google map and then you can highlight all of this sort of organism type in pink. If you click on a button and see where they are localized around the globe. But then if the climate increases by five degrees, then you can click another button and see what happens. Does that organism increase or decrease there? Does another microbial typing [00:17:00] green become more abundant? Speaker 3: The methods you use that you apply to your research. So often we're results oriented with science or at least to the public, you know, what did you find out? It becomes more important than how did you find it out? Can you give us some sense of your methods to doing the research that you do? Speaker 4: I think that the methods, as I mentioned earlier, that's been a limitation to my particular field, but that [00:17:30] also makes it kind of fun because we're always trying to develop better methods and new methods to be able to investigate these systems. And so it's quite challenging, which is something I like. So the method in my own lab that we're developing are different kinds of what I call omix quoting. Oh, mixed methods. So that's everything from sequencing everything, which would be metogenomic x to extracting RNA and [00:18:00] sequencing that. That would be looking at express genes. That's Meta transcriptomics or extracting all the proteins and looking at that. That would be metaproteomics. You can even do the metabolites metabolomics. So these are the current methods that are stated. The art right now for looking at these kinds of complex communities. Speaker 6: [inaudible] [inaudible] Speaker 5: this is k [00:18:30] a l x Berkeley. The show is spectrum. I'm Brad swift. Our guest is professor Janet Jansen, microbial ecologist at Lawrence Berkeley lab and UC Berkeley. Speaker 3: In your experience working on these large projects and also then working in small projects, I'm curious about the, the idea of big science versus small science. You know, the individual scientists toiling [00:19:00] away versus the big group that gets together and decides what they'll do and [inaudible]. Speaker 4: So personally I, I'm a big science kind of person. I definitely appreciate the value of a small science than I do have some smaller targeted projects. I moved to Berkeley lab about five years ago. I was a professor in Sweden before that and my funding was more individual, smaller projects in Sweden. But uh, one of the reasons I came to Berkeley lab was because of the big team science. I really [00:19:30] like that I'm a super collaborator and I can see the value of having people with different skills working together to tackle some really big problems. [inaudible] Speaker 3: and I suppose the culture then becomes really important to the group, the dynamics, the sharing, the openness. And how does that happen, do you think? Have you seen it work well and work badly? Speaker 4: Oh, it's very important. So you had to choose your collaborations as well and sometimes if they, the dynamics [00:20:00] aren't working, then it might be time to rethink the collaborations and revise it in a certain way. But ideally you have people that are so motivated that they are, I know that start delisting, but in the best case situation you have people that are so motivated towards a specific goal that it works quite well. There is an example of one project that is ongoing right now at the lab. It's called the next generation ecosystem [00:20:30] experiment in the Arctic, which is looking at the impact of climate change on permafrost communities. And that's the big doe funded project that involves probably hundreds of researchers at different laboratories, different doe laboratories and universities that are all focusing on one location in Barrow, Alaska, using all of the different tools available at the national labs and expertise at universities as well. Speaker 3: [00:21:00] And how long has that been going on? Speaker 4: It's been about a year and a half. It's a new project, but I'd like it because it has the necessary funding. Of course, when you spread it out, you know, everybody gets a little chunk of it, but it enables incredible things to be done at that site. It's just so much fun to go to these meetings and hear about the lidar sensing team and the modeling team and the hydrology team with their sleds and the geochemists go [00:21:30] in and my part is the microbial ecology. We get deep cores and we extract DNA and sequence them. It's just really a lot of fun Speaker 3: and there's a lot of emphasis on trying to encourage young people to get into science, technology, math. Is there really an opportunity in this field for, for people? Speaker 4: I have to say that right now it's a huge opportunity and there aren't enough persons educated in this field [00:22:00] to be able to fill these growing companies that are starting up. I'm getting several calls from companies that are asking for postdocs from my lab if they're interested in joining and if I were starting right now as a biologist, I would definitely look into bioinformatics and also the metagenome mix fields because these are the sorts of persons that there aren't that many yet. It's not that widespread yet [00:22:30] and there are companies that really need that expertise. Speaker 3: Would you characterize both of those briefly? Speaker 4: The bioinformatics would be more of generation of software algorithms, ways to look at these big data that are generated from different kinds of biological samplesSpeaker 3: and that might include visualization as well as other normal text output kind of a thing. Speaker 4: Yeah, absolutely. Everything from the database [00:23:00] management to the visualization of the data and things in between. The statistical analysis, that's a huge growth area and I predict this is going to continue because the data is just getting bigger. It's not going away from that a genomics and these other kinds of omix areas. I think that that would also involve some computing skills, but in addition to differentiate it from bioinformatics, more of the combination with lab skill. Speaker 3: [00:23:30] Janet Johnson. Thanks very much for coming on spectrum. Speaker 4: Thank you. I really enjoyed it. Speaker 3: Well, we'd like to mention a few of the science and technology events locally over the Speaker 7: next two weeks. Rick Karnofsky joins me for the calendar. The Saturday the science of cow lecture will be given by Dr Nadir Mirabal Fathi. The lecture is entitled, connecting infant decimal to infinity, the search for dark matter. [00:24:00] He will speak about a new class of elementary particles known as weakly interacting massive particles or Wimps to resolve inconsistencies in our understanding of the nature at both extreme, large and small scales and how they are connected together. He will also explore the experimental efforts to detect these particles. Interest real laboratories. Nadir r Mirabal Fathi earned Phd in elementary particle physics and cosmology at the University of Paris. He did his postdoctoral [00:24:30] studies at UC Berkeley and has been an associate research physicist at UC Berkeley since 2008 the lecture is Saturday, May 18th at 11:00 AM in room 100 of the genetics and plant biology building. Makerfair. The self-proclaimed greatest show and tell on earth is this weekend, May 18th and 19th at San Mateo fairgrounds. Speaker 7: We talked last year with Tony to rose and Michelle, who? Bianca. Two of the founders of young makers about [00:25:00] the maker fair. Find our interview with them@itunesuortinyurl.com slash calix spectrum one day prices range from $15 to $30. Highlights of this year's maker fair include KQ [inaudible] kitchen sisters with their new radio series, the making of what people make in the bay area and why NASA makers with astronauts, John Grunsfeld, Dennis Bartell's discussing building the new exploratorium, [00:25:30] how to tie a perfect neck tie with Nobel prize physicist Arno Penzias, DIY research with Tekla labs and amazing science. Tornadoes, smoke rings and more. For more information, visit makerfair.com that's maker F A I r e.com the long nose Stuart brand. It's presenting on reviving extinct species on Tuesday, May 21st [00:26:00] at the San Francisco Jazz Center, two Oh one Franklin Street at 7:30 PM tickets are $15 he'll summarize the progress of current de extinction projects including the Europe's Oryx Australia is gastric brooding frog and America's passenger pigeon. Speaker 7: He'll also discuss some of the ancient ecosystem revival projects such as Pleistocene Park in Siberia. New Genomic technology can reassemble the genomes of extinct species [00:26:30] whose DNA is still recoverable from museum specimens and some fossils. Sorry. Jurassic Park fans. No dinosaurs. It is hoped that the jeans unique to the extinct animals can brought back to life in the framework of the genome of the closest living relative. For more information, visit long now.org now Rick Karnofsky and I present to news stories. Alberto Saul from Brown University and colleagues [00:27:00] published an article in science on May 9th that suggests the water that is on the moon came from Earth. The team measured the relative abundance of deuterium that is heavy hydrogen that contains an extra neutron to hydrogen in the water, found in small bubbles of volcanic glass and Melt inclusions in moon rocks. They found the ratio was very similar to the ratio found on earth and from carbonaceous chondrites meteorites that are thought to have supplied [00:27:30] the earth with water. Speaker 7: Higher. Deuterium levels were expected by some who had hypothesized the comments from the Kuyper belt in Oort cloud could have been the source of the Moon's water. If the moon's water did come from Earth, it is likely the earth already had this water when the moon was formed. Some four and a half billion years ago when the earth and another Mars sized planet collided. However, such a collusion may have been hot enough to vaporize the lunar water. There is sir now [00:28:00] debating whether it may have been retained because of the earth's gravity or because the moon shared some of the earth's high temperature atmosphere when it formed pregnant mothers exposure to the flu was associated with a nearly four fold increased risk that their child would develop bipolar disorder in adulthood. In a study funded by the National Institutes of health. The findings add to mounting evidence of possible shared underlying causes and illness processes [00:28:30] with schizophrenia, which some studies have also linked to prenatal exposure to influenza, principal investigator Allen Brown and MD mph of Columbia University says prospective mothers should take common sense preventative measures such as getting flu shots prior to and in early stages of pregnancy and avoiding contact with people who are symptomatic in spite of public health recommendations, only a relatively small fraction of such women [00:29:00] get immunized. Speaker 7: The weight of evidence now suggests that benefits of the vaccine likely outweigh any possible risk to the mother or the newborn. Brown and colleagues reported their findings online. May 8th, 2013 in the Journal of the American Medical Association Psychiatry Speaker 2: [inaudible]. The music heard during the show is written and produced by Alex Simon. [00:29:30] Thank you for listening to spectrum. Had comments about the show, please send them to us via email or email address is spectrum dot k a l s@yahoo.com join us in two weeks at this same time. Hosted on Acast. See acast.com/privacy for more information.

Janet Jansson is the Senior Staff Scientist in the Earth Sciences Division at Lawrence Berkeley National Lab. Her expertise is in molecular microbial ecology and “omics” approaches with a focus on soil, marine sediment and human gut environments.TranscriptSpeaker 1: Spectrum's next. Speaker 2: Okay. Speaker 1: Welcome to spectrum the science and technology show on k a l x Berkeley, [00:00:30] a biweekly 30 minute program, bringing you interviews featuring bay area scientists and technologists as well as a calendar of local events and news. Speaker 3: Good afternoon. I'm your host, Brad Swift. Today's interview is with Janet Jansen, UC Berkeley, adjunct professor of molecular microbial ecology. She is a senior staff scientist in the Earth Sciences Division at Lawrence Berkeley National Lab and president elect of the International Society of microbial [00:01:00] ecology. Her expertise is in the area of molecular microbial ecology and Omix approaches with a focus on soil, marine sediment and human gut environments. Today she talks about the human microbiome project, the Earth microbiome project and American Gut, a crowdsourced research project. Onto that interview. Janet Jansen, welcome to spectrum. Hi, what'd you give us a short description [00:01:30] of microbial ecology and give some examples of complex microbial communities. Speaker 4: Sure. So microbial ecology is the study of micro organisms in the environment and their interactions with other microorganisms, plants, animals, that particular habitat that they happen to be living in. So it's really not just studying a single microorganism, but a community of microorganisms. Uh, so some examples [00:02:00] of complex communities. Well, the most complex ecosystem is soil and that's because it has such a diversity of microorganisms and it's really packed full of microbes. So there's so many microorganisms living in soil. So that combined with the diversity makes it a very complex system. The human ecosystem is very complex. Our own intestines have a very complex microbial community. [00:02:30] The oceans or other examples, sediments. So I think this is my community college that you had to think differently than one would when you study organisms in pure culture and their physiology is much more complex Speaker 3: and microbial research seems to have jumped in stature in the past few years. You have a broader view of it than I do. What's your take on the trajectory of microbial research? I think Speaker 4: [00:03:00] particularly the microbial ecology part has increased in stature recently. Microbiology as a field has been around for a long time. But the thing that I think has really boosted the field of microbial ecology is the advent of these new technologies, the new tools to be able to really look at these complex communities and understand them. Until I guess it was about the 1980s there wasn't [00:03:30] any way to really look at these micro organisms in soil. Again, I'll use that as an example, unless you cultivated them onto augur media or looked at them in a microscope. So when the field was limited to looking at what was possible to cultivate, that was only a fraction of the microorganisms that live in soil habitat. So probably fewer than 10% could be cultivated. So the majority of the organisms that were there, [00:04:00] nobody knew anything about them. Their identities or their functions were really unknown. Speaker 4: So it was considered like a black box eco system. But after the late, I guess the 80s and into the 90s there were the developments in DNA extraction techniques. So it was possible to extract DNA from soil and then came PCR amplification methods and methods to be able to amplify specific [00:04:30] pieces of DNA that you had extracted that made it possible to actually study soil microorganisms without cultivating them. And now we have these deep sequencing technologies, so it's really made it much easier to do very deep analysis of these communities and not have to rely on cultivation. Speaker 3: The human microbiome project is in its last year. What were the goals of it and can you speak to that about what the goals were and what you think [00:05:00] you've found out? Speaker 4: The first stage of the h and p was to sequence different bodies sites and understand which micro organisms are residing in different sites in the human body. And so this was looking at a large cohort of humans, healthy humans, and just basically understanding who are the microbial inhabitants of the human body. So that part is winding down. We have that knowledge now. We know that there are different micro organisms that live on your skin, [00:05:30] then in in your gut for examples and also in the oral cavity. So these organisms are specialized to live in different parts of the human body and there are differences between different individuals though. So that means that each human has their own individual microbiome and it can almost be used as a fingerprint. So that was a successfully completed project. The next stage there has been a recent call too, I think it's even called h and p two [00:06:00] to go the next step. So to use other kinds of methods to look at not only which microorganisms are there, but what are they doing. So this would be looking at the functional capabilities of the human microbiome. Another thing that is still ongoing with the h and p is looking at how does disease influence the human microbiome and vice versa. What is the correlation with the microorganisms living with us and disease? And it seems like there are many different links between many [00:06:30] human disease that send the human microbiome Speaker 3: [inaudible] [inaudible]. Speaker 5: Our guest today is microbiologists, Janet Jansen. In the next segment she talks about the microbiome and disease correlation. This is k a l x, Berkeley. Speaker 3: Well, and often in science there's a lot of correlation [00:07:00] that goes on and sometimes you get fooled by the correlation. Sometimes you don't. Are there strategies you use in terms of validating what you think correlates? Speaker 4: Oh, correlations are can be quite challenging. Definitely. So, um, that's an interesting question because then one of the things that is very tricky is if you find a difference in an environmental sample, for example, with the civic treatment or in a human with disease often all we have, [00:07:30] we can then say, well it's correlated to this organism that is higher in abundance or it's correlated to this protein that is higher or lower in abundance. That's a little frustrating. So that the next step, and we're not quite there yet in this field, would be then to say, okay, go beyond correlations and then actually do the proof, you know, to take that organism like Cox postulates, you then prove that this correlation that you see is actually [00:08:00] occurring. But it's difficult with these complex samples, like I was saying before, because you have to move away from the complex environment where you have all these different factors. Speaker 3: So the complexity defeats you in a way because you can't isolate the specific from the general. Exactly. Exactly. And so within this correlation of disease, are there particular diseases that seem to be top priorities in a sense or are most likely to be effected by [00:08:30] the microbiome? An example of Crohn's diseases, Speaker 4: Crohn's disease is the example. I would give us a very clear example and also other inflammatory bowel diseases where there has already been established a link between the gut microbiome and the disease. The details are still under investigation, but there is a difference in the micro organisms that inhabit the intestine in individuals that have Crohn's disease compared to healthy. [00:09:00] So that's known. Speaker 3: And is that the case with ulcers as well? Or they were sort of one of the first, it seems that had this association with the microbiome in the gut, Speaker 4: right. So systemic ulcers, there was a Nobel prize awarded for the discovery of [inaudible] go back to Pylori as the cause of ulcers in the stomach. And so that's a good example, this specific microorganism that can contribute to a disease. And then of course a lot of medications were subsequently [00:09:30] developed to dampen hillcoat back to pylori through new research. We know that there is a considerable diversity of microorganisms in the stomach that people weren't aware of before using these techniques and also in your teeth and then in the oral cavity. There's a very large diversity. I should mention that one of the things that is a really hot topic right now is the link between the brain and the human microbiome, including [00:10:00] the gut microbiome because it's known that some of the metabolites that are produced by these intestinal microbes can pass the blood barrier and then migrated essentially in impact the brain, so some current research is looking at the link between autism and schizophrenia, these kinds of things. Then I think that's really interesting. That's one future direction of the field. Speaker 3: The new initiative in brain mapping exactly [00:10:30] now ties that together. That would be great. At least the findings here was just a new funding. Speaker 4: Yeah, I know. I don't know if they've really decided to make that link for funding, but it probably will come. Speaker 3: Can you talk a bit about American gut and how it's set up to help people figure out their own microbiome? Speaker 4: Sure. So the American get is, it's a relatively new way of doing research [00:11:00] is crowdsourcing. And the idea is that if a person such as myself is interested in knowing quip, my gut microbiome is I can pay a small amount, it's like $100 to get my sample sequence. So that is the way that the project is funded. And so this project, it had a funding goal, I think it was $300,000 to be able to launch the sequencing. And so there was the campaign [00:11:30] and it was sent out to the community and through connections such as Facebook and another with this nice little carrot that if you pay $100 you can get your microbiome. And in addition to gut, it could be your skin sample, oral cavity, your pet. And so this idea really caught on and is a good example of crowdsourcing for funding. Speaker 3: And how are people able to leverage that information? [00:12:00] Is there some characterization that you do as well? Speaker 4: The data that they get back is, it's different kinds of information. So first which micro organisms do I have? That's kind of fun to know. It's sort of like 23 and me where you get information back about which genes you have in, which kind of markers for different things. So depending on your microbial community composition, you may have markers that are more indicative of health, certain kinds of diets like [00:12:30] vegetarian or a protein rich diet, even obesity, there's certain microbial indicators of obesity. So that's just interesting. Another thing that is valuable for the consumer, the person who does this is that you can compare your microbiome to everybody else's. It's all anonymous of course. And nobody knows who's this, who's, but you have your own data and can see how your microbiome fits into a pattern. So do you cluster [00:13:00] with obese people or with a disease type microbiome or a certain kind of eating pattern Speaker 3: and are these online tools that you have available through American gut for people to do this kind of characterization? Speaker 4: So the analysis has to be done by the actual scientists that are doing the samples because it's still quite elaborate and involves a lot of bioinformatics. So currently it's not possible [00:13:30] to do a lot of that on your own, but still to get an output, the actual data, the results of the analysis is what the individual can get through this project. Speaker 2: [inaudible] you were listening to spectrum on a k a l x Berkeley. Our guest today is Janet Jensen. In the next segment she talks about the earth microbiome project. Speaker 3: [00:14:00] Can you talk a bit about the earth microbiome project and maybe differentiate it from the human project? Speaker 4: Yeah, sure. So the Earth microbiome project, which I'll call the emp, is, um, instead of just looking at humans, it's including basically all of earth. So it has a very lofty goal of understanding earth microbial diversity. That project also relies [00:14:30] on collaborators, so it's sort of a crowdsourcing project as well, but limited to the scientific community. So the way that Earth microbiome project works is if a collaborator has an interesting set of samples, for example, from the deep sea or from Yellowstone hot springs that have the required kinds of environmental data, so Ph, nutrients, things like that. Then they can [00:15:00] send an email to the steering committee and say, well, would this study be of interest to the earth microbiome project to the ENP? And then the steering committee looks through the data and decides whether the environmental data is sufficient and if the samples are filling a hole and providing novel information and if so the samples are accepted and the sequencing is done without any costs to the investigator. That's the win win scenario for the emp [00:15:30] because the investigator does of course provide the funding for the study and collection of the samples and the emp provides the funding for the sequencing. Now the funding for emp is also kind of fuzzy because it's through different kinds of companies that have supported by providing regions or equipment and then in turn they get advertisement through the emp that they're sponsors of the project. And so that [00:16:00] also seems to be quite successful. Speaker 3: And the intent again to build a catalog Speaker 4: basically, yes, to build a catalog to find out who's there and are there patterns. The nice thing about heading samples from so many different disparate environments is that you can see, well does this particular microorganism occur across different kinds of environments or is it really endemic only to one kind of habitat? And if you tweak the environment, [00:16:30] for example, with climate change to have increases or losses of certain members of the community that are predictive, one of the aims is to have something like a Google map and then you can highlight all of this sort of organism type in pink. If you click on a button and see where they are localized around the globe. But then if the climate increases by five degrees, then you can click another button and see what happens. Does that organism increase or decrease there? Does another microbial typing [00:17:00] green become more abundant? Speaker 3: The methods you use that you apply to your research. So often we're results oriented with science or at least to the public, you know, what did you find out? It becomes more important than how did you find it out? Can you give us some sense of your methods to doing the research that you do? Speaker 4: I think that the methods, as I mentioned earlier, that's been a limitation to my particular field, but that [00:17:30] also makes it kind of fun because we're always trying to develop better methods and new methods to be able to investigate these systems. And so it's quite challenging, which is something I like. So the method in my own lab that we're developing are different kinds of what I call omix quoting. Oh, mixed methods. So that's everything from sequencing everything, which would be metogenomic x to extracting RNA and [00:18:00] sequencing that. That would be looking at express genes. That's Meta transcriptomics or extracting all the proteins and looking at that. That would be metaproteomics. You can even do the metabolites metabolomics. So these are the current methods that are stated. The art right now for looking at these kinds of complex communities. Speaker 6: [inaudible] [inaudible] Speaker 5: this is k [00:18:30] a l x Berkeley. The show is spectrum. I'm Brad swift. Our guest is professor Janet Jansen, microbial ecologist at Lawrence Berkeley lab and UC Berkeley. Speaker 3: In your experience working on these large projects and also then working in small projects, I'm curious about the, the idea of big science versus small science. You know, the individual scientists toiling [00:19:00] away versus the big group that gets together and decides what they'll do and [inaudible]. Speaker 4: So personally I, I'm a big science kind of person. I definitely appreciate the value of a small science than I do have some smaller targeted projects. I moved to Berkeley lab about five years ago. I was a professor in Sweden before that and my funding was more individual, smaller projects in Sweden. But uh, one of the reasons I came to Berkeley lab was because of the big team science. I really [00:19:30] like that I'm a super collaborator and I can see the value of having people with different skills working together to tackle some really big problems. [inaudible] Speaker 3: and I suppose the culture then becomes really important to the group, the dynamics, the sharing, the openness. And how does that happen, do you think? Have you seen it work well and work badly? Speaker 4: Oh, it's very important. So you had to choose your collaborations as well and sometimes if they, the dynamics [00:20:00] aren't working, then it might be time to rethink the collaborations and revise it in a certain way. But ideally you have people that are so motivated that they are, I know that start delisting, but in the best case situation you have people that are so motivated towards a specific goal that it works quite well. There is an example of one project that is ongoing right now at the lab. It's called the next generation ecosystem [00:20:30] experiment in the Arctic, which is looking at the impact of climate change on permafrost communities. And that's the big doe funded project that involves probably hundreds of researchers at different laboratories, different doe laboratories and universities that are all focusing on one location in Barrow, Alaska, using all of the different tools available at the national labs and expertise at universities as well. Speaker 3: [00:21:00] And how long has that been going on? Speaker 4: It's been about a year and a half. It's a new project, but I'd like it because it has the necessary funding. Of course, when you spread it out, you know, everybody gets a little chunk of it, but it enables incredible things to be done at that site. It's just so much fun to go to these meetings and hear about the lidar sensing team and the modeling team and the hydrology team with their sleds and the geochemists go [00:21:30] in and my part is the microbial ecology. We get deep cores and we extract DNA and sequence them. It's just really a lot of fun Speaker 3: and there's a lot of emphasis on trying to encourage young people to get into science, technology, math. Is there really an opportunity in this field for, for people? Speaker 4: I have to say that right now it's a huge opportunity and there aren't enough persons educated in this field [00:22:00] to be able to fill these growing companies that are starting up. I'm getting several calls from companies that are asking for postdocs from my lab if they're interested in joining and if I were starting right now as a biologist, I would definitely look into bioinformatics and also the metagenome mix fields because these are the sorts of persons that there aren't that many yet. It's not that widespread yet [00:22:30] and there are companies that really need that expertise. Speaker 3: Would you characterize both of those briefly? Speaker 4: The bioinformatics would be more of generation of software algorithms, ways to look at these big data that are generated from different kinds of biological samplesSpeaker 3: and that might include visualization as well as other normal text output kind of a thing. Speaker 4: Yeah, absolutely. Everything from the database [00:23:00] management to the visualization of the data and things in between. The statistical analysis, that's a huge growth area and I predict this is going to continue because the data is just getting bigger. It's not going away from that a genomics and these other kinds of omix areas. I think that that would also involve some computing skills, but in addition to differentiate it from bioinformatics, more of the combination with lab skill. Speaker 3: [00:23:30] Janet Johnson. Thanks very much for coming on spectrum. Speaker 4: Thank you. I really enjoyed it. Speaker 3: Well, we'd like to mention a few of the science and technology events locally over the Speaker 7: next two weeks. Rick Karnofsky joins me for the calendar. The Saturday the science of cow lecture will be given by Dr Nadir Mirabal Fathi. The lecture is entitled, connecting infant decimal to infinity, the search for dark matter. [00:24:00] He will speak about a new class of elementary particles known as weakly interacting massive particles or Wimps to resolve inconsistencies in our understanding of the nature at both extreme, large and small scales and how they are connected together. He will also explore the experimental efforts to detect these particles. Interest real laboratories. Nadir r Mirabal Fathi earned Phd in elementary particle physics and cosmology at the University of Paris. He did his postdoctoral [00:24:30] studies at UC Berkeley and has been an associate research physicist at UC Berkeley since 2008 the lecture is Saturday, May 18th at 11:00 AM in room 100 of the genetics and plant biology building. Makerfair. The self-proclaimed greatest show and tell on earth is this weekend, May 18th and 19th at San Mateo fairgrounds. Speaker 7: We talked last year with Tony to rose and Michelle, who? Bianca. Two of the founders of young makers about [00:25:00] the maker fair. Find our interview with them@itunesuortinyurl.com slash calix spectrum one day prices range from $15 to $30. Highlights of this year's maker fair include KQ [inaudible] kitchen sisters with their new radio series, the making of what people make in the bay area and why NASA makers with astronauts, John Grunsfeld, Dennis Bartell's discussing building the new exploratorium, [00:25:30] how to tie a perfect neck tie with Nobel prize physicist Arno Penzias, DIY research with Tekla labs and amazing science. Tornadoes, smoke rings and more. For more information, visit makerfair.com that's maker F A I r e.com the long nose Stuart brand. It's presenting on reviving extinct species on Tuesday, May 21st [00:26:00] at the San Francisco Jazz Center, two Oh one Franklin Street at 7:30 PM tickets are $15 he'll summarize the progress of current de extinction projects including the Europe's Oryx Australia is gastric brooding frog and America's passenger pigeon. Speaker 7: He'll also discuss some of the ancient ecosystem revival projects such as Pleistocene Park in Siberia. New Genomic technology can reassemble the genomes of extinct species [00:26:30] whose DNA is still recoverable from museum specimens and some fossils. Sorry. Jurassic Park fans. No dinosaurs. It is hoped that the jeans unique to the extinct animals can brought back to life in the framework of the genome of the closest living relative. For more information, visit long now.org now Rick Karnofsky and I present to news stories. Alberto Saul from Brown University and colleagues [00:27:00] published an article in science on May 9th that suggests the water that is on the moon came from Earth. The team measured the relative abundance of deuterium that is heavy hydrogen that contains an extra neutron to hydrogen in the water, found in small bubbles of volcanic glass and Melt inclusions in moon rocks. They found the ratio was very similar to the ratio found on earth and from carbonaceous chondrites meteorites that are thought to have supplied [00:27:30] the earth with water. Speaker 7: Higher. Deuterium levels were expected by some who had hypothesized the comments from the Kuyper belt in Oort cloud could have been the source of the Moon's water. If the moon's water did come from Earth, it is likely the earth already had this water when the moon was formed. Some four and a half billion years ago when the earth and another Mars sized planet collided. However, such a collusion may have been hot enough to vaporize the lunar water. There is sir now [00:28:00] debating whether it may have been retained because of the earth's gravity or because the moon shared some of the earth's high temperature atmosphere when it formed pregnant mothers exposure to the flu was associated with a nearly four fold increased risk that their child would develop bipolar disorder in adulthood. In a study funded by the National Institutes of health. The findings add to mounting evidence of possible shared underlying causes and illness processes [00:28:30] with schizophrenia, which some studies have also linked to prenatal exposure to influenza, principal investigator Allen Brown and MD mph of Columbia University says prospective mothers should take common sense preventative measures such as getting flu shots prior to and in early stages of pregnancy and avoiding contact with people who are symptomatic in spite of public health recommendations, only a relatively small fraction of such women [00:29:00] get immunized. Speaker 7: The weight of evidence now suggests that benefits of the vaccine likely outweigh any possible risk to the mother or the newborn. Brown and colleagues reported their findings online. May 8th, 2013 in the Journal of the American Medical Association Psychiatry Speaker 2: [inaudible]. The music heard during the show is written and produced by Alex Simon. [00:29:30] Thank you for listening to spectrum. Had comments about the show, please send them to us via email or email address is spectrum dot k a l s@yahoo.com join us in two weeks at this same time. See acast.com/privacy for privacy and opt-out information.